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Abstract 
 
The presence of microbial commensals in the gut requires the establishment of a complex 
network of reciprocal interactions between the microbiota and the host immune system to 
allow nutrient absorption while preventing undesired mucosal immune responses. Despite 
these homeostatic mechanisms, during intestinal inflammation alterations of the 
microbiota composition, namely dysbiosis, trigger abnormal immune responses. Indeed, 
an exaggerated T cell response against dysbiotic microbial antigens has been causally linked 
to the onset of Inflammatory Bowel Diseases (IBD), a family of intestinal autoimmune 
disorders. Moreover, also iNKT cells, a subset of non-conventional T cells that can recognize 
bacterial lipidic antigens and shape the gut microbial community, have been associated to 
IBD pathogenesis. 
Here, we aimed at investigating the functional crosstalk between gut microbiota and the 
mucosal immune system during inflammation and upon induction of microbial dysbiosis. 
Ultimately, the goal of this project was to evaluate the therapeutic potential of gut 
microbiota manipulation on the mechanisms contributing to the resolution of intestinal 
inflammation. 
We observed that inflammation-induced and antibiotic-driven types of dysbiosis are 
phenotypically and functionally modifying CD4+ T and iNKT cells activity. Moreover, during 
intestinal inflammation, the experimental manipulation of the microbiota community 
through Faecal Microbiota Transplantation (FMT) reduces colonic inflammation and 
initiates the restoration of intestinal homeostasis through a modulation of the whole 
mucosal immune response. Indeed, FMT leads to an increase in IL-10 production by innate 
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and adaptive immune cells, including CD4+ T cells, iNKT cells and Antigen Presenting Cells, 
and reduces the ability of these cells to present MHCII-dependent bacterial antigens to 
colonic T cells.  
Further, we performed a comprehensive analysis on intestinal iNKT cells isolated from 
surgical specimens of active IBD patients and non-IBD donors, generating stable cell lines 
and clones for in vitro functional assays. We here report that iNKT cells with a defined pro-
inflammatory profile are enriched in the intestinal lamina propria of IBD patients and that 
exposure to the mucosa-associated microbiota drives their pro-inflammatory activation, 
inducing direct pathogenic activities against the epithelial barrier integrity. 
Collectively, we provided solid evidence that a strict crosstalk between the gut microbiota 
and the intestinal conventional and non-conventional T cells exists. Antibiotic-associated 
dysbiosis has immunostimulatory functions, indicating the need of a careful evaluation of 
antibiotic administration to patients suffering from autoimmune disorders, such as IBD. 
Moreover, our results demonstrate the capability of FMT to therapeutically control 
intestinal experimental colitis and pose FMT as a valuable therapeutic option in immune-
related pathologies. In addition, we generated fundamental knowledge about the 
pathogenic functions exerted by human intestinal iNKT cells as a consequence of the 
interaction with mucosa-associated microbiota communities. This suggests that the 
selective targeting of iNKT cells or the modulation of their functions may be explored as a 
potential therapeutic tool in IBD. 
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1 Introduction 
 
In the gut, the divergent needs of nutrient absorption and the maintenance of a strong host 
immune defense coexist [1][2]. The intestine is indeed a unique organ, being the most 
comprehensive reservoir of commensals of the human body, and a vast potential portal for 
pathogen entry [3]. To comply its duties while overcoming the obstacles that originate from 
them, the mucosal immune system has developed a complex system to counterbalance 
immunity, at risk of overstimulation by the microorganisms, and tolerance, required for 
food intake [4]. To this aim, the intestine has established a network of interactions among 
different players, such as the specialized epithelial cells, the intraepithelial and lamina 
propria immune cells and the gut microbiota. 
In this Chapter the unique features orchestrating the mucosal immune system will be firstly 
addressed, focusing on physical and immunological barriers. Then the emerging role of gut 
microbiota in the shaping of the host response will be unravelled. Finally, the effects of a 
pathological dysregulation of such fine-tuned mechanisms of crosstalk in Inflammatory 
Bowel Diseases will be described. 
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1.1 The intestinal epithelial barrier 
In contrast to secondary lymphoid organs, including lymph nodes and spleen, a distinctive 
characteristic of mucosal tissues like the gut is the close, extensive and bidirectional 
collaboration between the immune system and epithelial cells [4]. The human intestinal 
epithelial barrier is composed by a monolayer of approximately 20 billion tightly joined 
enterocytes that represents the first line of defense of the host [1], [5]. The surface area of 
this epithelium is to the order of 400 m2 since it is formed into millions of fingerlike villi in 
the small bowel and crypts in the colon [2]. This spatial organization optimizes the 
absorption of nutrients. 
The intestinal epithelial barrier function is essential for health and relies on intercellular 
junctions that maintain epithelial cohesiveness while regulating its selective permeability 
[5]. These specialized cell membrane structures are referred to as tight junctions (TJs) and 
adherens junctions (AJs). These structures are composed by multimeric transmembrane 
protein complexes that in TJs include proteins of the claudin, occludin and junctional 
adhesion molecules (JAM) families and in AJs include nectins and e-cadherin [6]. They seal 
epithelial cells forming homo- or etero- dimers with the corresponding structures on the 
adjacent cells. Junctions have also a cytosolic plaque in charge of intracellular signal 
transduction, whose main components are adaptor proteins, such as ZO-1, that contain 
several protein-protein interaction motifs [1], [6]. While the transcellular passage across 
the epithelium requires an active transport, paracellular spaces between cells allow passive 
diffusion. Intestinal epithelial TJs permit the diffusion of water and electrolytes but they 
largely limit the absorption of water-soluble proteins that exceed 0.4 nm in diameter [6].  
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For decades the intestinal epithelium has been considered to play a passive role of physical 
barrier. We now know that enterocytes are a family of specialized and highly dynamic cells 
with active functions in the maintenance of the organ homeostasis [2]. They originate from 
pluripotent highly proliferative cells, called transit amplifying cells, derived from Lgr5+ stem 
cells located at the basis of the crypts. Throughout their migration towards the top of the 
villous the cells decrease their proliferation rate depending on a Notch and Wnt signaling 
gradient and differentiate into absorptive enterocytes, goblet cells, Paneth cells or M cells 
[4]. Absorptive enterocytes have the task to absorb nutrients and are the most abundant 
cell type [4]. Goblet cells are the main producers of mucin glycoproteins, components of 
the glycocalix and mucous layers lying on top of the epithelium [7]. Paneth cells secrete 
anti-microbial peptides in response to gut microbiota in a MyD88 dependent manner [8]. 
M cells play an important role in antigen uptake and transfer to the Peyer’s patches, small 
lymphoid follicles lying underneath the epithelium [2]. 
 
1.2 The mucus layers 
The mucus layers oversee the containment of the gut microbiota in the intestinal lumen 
and attenuate the friction of the food bolus against the epithelium [5]. 
The specialized Goblet cells secrete high amounts of mucus, which is composed by mucin 
protein backbones with O-linked glycosilation. Once secreted, mucins become hydrated 
and expand forming a net-like gel sub-structured in three layers [5]. The first one is formed 
by membrane-bound mucins associated with the colonic epithelial cells and it is referred 
to as glycocalyx. The second layer is the tightly crosslinked inner layer which is primarily 
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composed by the secreted mucin MUC2 [7]. This layer is maintained sterile thanks to the 
high gel density and the presence of high doses of antimicrobial peptides produced by the 
close epithelium [9]. The outermost layer is less dense and viscous since it is produced by 
proteolysis of the inner layer. The outer layer allows the gut microbiota to create a 
specialized niche for mucus-associated bacteria [7]. The mucus turnover is fast and takes 
place in a few hours. As it is proteolyzed and extruded in the lumen, it binds bacteria and 
gets expulsed with the peristalsis. This mechanism limits the bacteria approaching the 
epithelium, without precluding access to metabolites and, in some cases, toxins [5]. This 
observation is demonstrated by the evidence that mice lacking Muc2 expression (Muc2-/-) 
experience a reduction of the mucus thickness, an enhanced access of bacteria to the 
epithelium and the spontaneous development of intestinal inflammation [10].  
Mucins can be either secreted or be transmembrane and, besides their structural function, 
they can also actively signal intracellularly and have immunomodulatory activities [11]. For 
instance, MUC1 has been shown to have potent anti-inflammatory functions [12]. 
 
1.3 Antimicrobial peptides 
Antimicrobial peptides (AMPs) are one of the evolutionarily most ancient mechanism of 
defense against microbes developed by multicellular organisms [9]. Albeit many gut 
microbiota components are commensals that establish mutualistic relationships with the 
host, the huge numbers of bacteria present in the intestinal lumen represents a continuous 
threat for barrier integrity. To overcome this threat, Paneth cells secrete abundant AMPs 
which rapidly kill or inactivate microorganisms. The vast variety of microorganisms that the 
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host can encounter reflects the complexity and diversity of the AMPs it produces. Intestinal 
AMPs include defensins lysozymes, C-type lectins and cathelicidins [4]. They use different 
molecular mechanisms to kill bacteria but many of them target basic and essential cell wall 
structures of bacteria, such as peptidoglycan. In this way they act specifically against 
bacteria and they reduce the probability of resistance development [9]. Some of them, like 
lysozymes, have enzymatic activity to degrade peptidoglycan or cell wall components, 
others, like defensins and cathelicidins, physically insert into bacterial membranes leading 
to disruption of membrane potential and osmotic lysis [13]. Being a potent response 
against bacteria, they have been shown to have also anti-inflammatory and potential 
therapeutic activity during intestinal inflammation [14]. 
 
1.4 Intestinal antigen transport and presentation 
Besides exerting barrier functions, intestinal epithelial cells attend the important task to 
orchestrate mucosal immunity by modulating the immune response through tolerance 
induction as well as by directing the inflammatory response in the lamina propria. The huge 
surface area of the intestine is continuously in contact with a wide variety of antigens such 
as dietary proteins and carbohydrates, lipids, bacteria, fungi and viruses [2]. The fact that 
2% of dietary proteins can be found intact in blood circulation suggests the existence of 
breaches in the epithelial barrier. Indeed, several mechanisms of transcellular transport of 
antigens have been described.  
M (microfold) cells are specialized epithelial cells that reside in the follicle-associated 
epithelium (FAE) (Figure 1.1). The glycocalyx above M cells is thinner as compared to the 
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one on top of absorptive enterocytes [4]. This allows the access of particulate antigens that 
are taken up by M cells through various mechanisms including pinocytosis and receptor-
mediated endocytosis without any processing. It has been shown that transepithelial 
transport by M cells is facilitated by toll-like receptors engagement in the presence of 
bacteria [15]. Antigens transported by M cells are passed on to immature Dendritic cells 
(DCs) located close to the basolateral membrane of M cells. Loaded immature DCs migrate 
to the near Peyer’s patches and here they present antigens and trigger the adaptive 
response [15]. 
In addition, upon mucus secretion, Goblet cells are also able to sense bacterial luminal 
antigens and take them up. The transport of antigens by Goblet cells is referred to as goblet 
cell-associated passage (GAP) and it remains still largely unknown [7]. Experiments in mice 
challenged with fluorescently labelled dextran showed that the dye was primarily taken up 
by Goblet cells [16]. The size of the antigen that can be transported through this route is 
determined by mucus filtering and it is limited to low molecular weight (70kDa) soluble 
antigens. GAP specifically deliver antigens to CD103+ CX3CR1- DCs that engage Tregs cells 
and mediate tolerogenic functions [16]. 
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Figure 1.1 Intestinal antigen transfer from gut lumen to lamina propria. The intestinal epithelium 
orchestrates the activity of gut-associated lymphoid tissue (GALT) through different mechanisms.  
Specialized M cells constantly transport gut bacteria and antigens from the gut lumen into the Peyer’s 
patches. In the lamina propria Dendritic cells take up the antigens transported or directly sample 
them from the lumen. Lamina propria contains many CD4 T cells, macrophages, and IgA antibody–
producing plasma cells. Potentially tissue-damaging T cell responses may be inhibited by 
immunosuppressive cytokines and regulatory T cells. Adapted from TT MacDonald and G Monteleone, 
Science, 2005 [17]. 
 
As stated in Section 1.1, also tight junctions between epithelial cells can modulate the 
passage of small molecular weight antigens through paracellular diffusion. These antigens 
are thought to diffuse until the mesenteric lymph node (mLN) where they meet 
professional antigen presenting cells (APCs) that initiate an immune response. 
Finally, dendritic cells have been shown to be able to intercalate their dendrites between 
epithelial cells by expressing tight junction proteins (i.e. ZO-1) thus directly sampling the 
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antigens from the lumen [18] (Figure 1.1). These DCs express CX3CR1 chemokine receptor 
and trigger a pro-inflammatory adaptive immune response [18]. 
Dendritic cells are the most potent subset of APCs. Nonetheless, in the intestinal lamina 
propria antigens can encounter several types of professional antigen presenting cells such 
as monocytes, macrophages and B cells. These cells share the capability to internalize 
antigens in endocytic vacuoles, process them and load them on antigen presenting 
molecules. B lymphocytes can directly bind antigens on Ig surface molecules, whereas T 
cells require the presentation of a membrane-bound antigen to trigger their activation 
through T cell receptor (TCR) signaling cascade. Major Histocompatibility Complex (MHC) I 
and II present peptidic antigens of endogenous and exogenous origin to CD8+ T and CD4+ T 
cells respectively. More recently it has been identified a pathway for lipidic antigen 
presentation by members of the CD1 family [19]. 
Besides professional APC, intestinal epithelial cells have also been shown to be able to 
present antigens of both peptidic [20] and lipidic [21] nature and initiate an adaptive 
immune response. To note, the type and origin of the APC is critical to induce specific 
outcomes [22]. Indeed, for instance, it has been shown that lipidic antigen presentation by 
intestinal epithelial cells elicits a protective and regulatory response [23], while several  
evidences show that lipid specific intestinal T cells can exert pro-inflammatory and 
pathogenic functions in response to antigen presentation [24]. 
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1.5 T cell mediated mucosal immune response 
Initially, mucosal immunology was dominated by a focus on secretory IgA mediated 
immunity. We now know that T cells form an equally relevant component of cell-mediated 
immunity at mucosal sites [25]. During homeostasis, the most abundant subsets of 
intestinal T cells are CD8+ αβ T cells and intraepithelial γδ T cells [26]. The former form a 
population of tissue resident long-lived memory cytotoxic T cells that can be promptly 
reactivated in case of infections, thus securing the tissue with immunesurveillance activity. 
The latter exert both innate and adaptive cytotoxic functions, besides having a role in 
epithelial repair [26]. MHCII restricted CD4+ T cells are less frequent in the intestinal 
mucosa, but they can massively infiltrate the gut lamina propria in case of inflammation 
and contribute significantly to the pathology [27], [28]. 
In the mid-1980s, in vitro cloning of CD4+ T cells showed the existence of two distinct 
effector subsets [29]. One was referred to as T helper 1 (Th1), secreting pro-inflammatory 
cytokines such as IFNγ and TNF and is employed for defense against viruses and 
intracellular bacteria. The other was called T helper 2 (Th2) because it differentially 
secreted cytokines such as IL-4, IL-5 and IL-13 in response to parasitic infections. These two 
opposed subsets were shown to reciprocally suppress their development [30].  
The development of Th1 cells is induced by the production of IL-12 by APCs. This drives the 
activation of the signaling cascade of STAT1 leading to the expression of Tbet (T-box 
transcription factor expressed in T cells), the master regulator transcription factor of Th1 
subset [31]. IL-12 also induces STAT4 phosphorylation that, together with Tbet, triggers the 
production of IFNγ and TNF. Downstream, Th1 cells are driving B cell class switching to 
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opsonizing IgG and the activation of intracellular killing by macrophages. This way Th1 cells 
respond to intracellular bacteria and virus infections [25].  
Th2 cells differentiate mainly in response to helminth parasitic infections. Their 
differentiation is induced by IL-4 expression by innate immune cells and it is characterized 
by the phosphorylation of the STAT6 signaling cascade that, in turn, activates GATA3 
transcription factor [32]. Via the secretion of IL-4, IL-5 and IL-13 they orchestrate B cell class 
switching to IgE and the recruitment of granulocytes like mast cells, basophils and 
eosinophils [25]. 
In 2005, a third T helper cell subset, called Th17, was added to the Th1/2 paradigm [33]. 
Th17 cells are characterized by the production of IL-17A and IL-17F. Their differentiation is 
induced upon TGFβ, IL-23 and IL-6 secretion. These cytokines drive the phosphorylation 
cascade of STAT3 pathway that determines the expression of RORγt transcription factor. 
IL-17 is actively recruiting neutrophils that contribute to the elimination of extracellular 
bacteria and fungi. Intestinal Th17 cells have been clearly shown to contribute to Crohn’s 
disease pathogenesis [34],[35]. 
More recently, many mucosal immunologists are focusing their research on the 
characterization of several additional Th subsets, including IL-9 producing Th9 cells ad IL-
22 producing Th22. 
To deal with this arsenal of effector CD4+ T helper cells, the intestinal immune response 
deploys another subset of CD4+ T cells with potent immune suppressive functions, i.e. the 
regulatory T cells (Treg). This population was firstly described in 1995 by Sakaguchi et al. 
and it was initially identified by its expression of the IL-2 receptor α chain (CD25) [36]. Mice 
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transferred with thymocytes depleted of CD4+CD25+ T cells developed severe autoimmune 
diseases in several organs [36]. Later, Foxp3 was recognized as the master transcriptional 
regulator of Treg cells [37]. 
Also for Treg cells, a wide number of sub-populations have been defined, including Foxp3+ 
inducible Treg, Foxp3+ thymic Treg, Tr1 and regulatory Th17. The population described by 
Sakaguchi is the now called thymus-derived tTreg. Within 3 days after birth, these cells 
migrate to the periphery and become in charge of peripheric tolerance. Conversely, some 
CD4+ T cells, with a distinct TCR specificity, can exert regulatory activity once they are in the 
periphery if properly stimulated by APCs. This is the case of inducible iTreg cells [38]. 
Recent studies have questioned the idea that the above-described CD4+ T cell subsets 
represent stable populations. Indeed the Th17 cell lineage displays a marked plasticity 
having overlapping differentiation programs with Th1 and iTreg [39]. Foxp3 or Tbet 
expression in Th17 cells can induce a functional transition to Treg or Th1 cell state, 
respectevely. If the transition to iTreg suggests a clear role in the resolution of the 
inflammation, the functional meaning of Th17-Th1 plasticity remains elusive. Nonetheless 
it has been shown to greatly contribute to autoimmune pathogenesis in Crohn’s disease 
patients [35]. 
 
1.6 iNKT cells 
Invariant natural killer T (iNKT) cells were identified in the mid-1990s as a mature T cell 
subset with semi-inviariant T cell receptor (TCR) [40], [41]. iNKT cells, also called type 1 NKT 
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cells, bear a semi-invariantly rearranged αβ TCR which comprises an invariant α chain 
rearrangement (Vα14-Jα18 in mouse and Vα24-Jα18 in human) paired with a limited β 
chain repertoire (Vβ7, Vβ8 or Vβ2 in mouse and Vβ11 in human) [40]. However, in both 
mice and humans, TCR β chain diversity is achieved through the use of variable TCR Dβ and 
Jβ region that results in high level of complementarity determining region 3 (CDR3) 
diversity and thus polyclonal repertoire of multiple specificities [42]. 
iNKT cells recognize lipidic antigens presented by the MHCI-like molecule CD1d that has the 
unique characteristic to be non-polymorphic and greatly conserved among mammals 
(Figure 1.2). CD1d belongs to the larger family of CD1 complexes that includes CD1a, CD1b 
and CD1c molecules, all of which present lipid antigens rather than peptides to T cells. The 
antigens recognized by iNKT cells can be either of exogenous bacterial origin or of self-
origin [21], [43]. The best known iNKT TCR agonist is α-galactosylceramice (αGalCer), a 
bacteria- derived glycosphingolipid originally purified from a marine sponge [44]. Unlike all 
mammalian glycosphingolipids which have β-linked sugars, αGalCer contains an α linkage 
of the sugar to the ceramide lipid, that has been shown to be essential for its high affinity 
with the TCR and its antigenic potency. Thanks to the αGalCer strong and conserved 
recognition, iNKT cells can be easily detected with αGalCer-loaded tetramers [45]. Similar 
antigens have been isolated also from gut commensals [21], [46] and from pathogens [47]. 
iNKT cells are also autoreactive. However, self-antigens are often structurally variable and 
engage the CD1d with low affinity. Some reported candidate antigens are members of the 
glycosphingolipid family as well [48]. Also completely different compounds have been 
described as self-antigens, like a peroxisome-derived lysophosphatidylethanolamine 
important for positive thymic selection [43].  
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Besides antigen presentation, iNKT cells can be activated also by innate-like stimuli such as 
cytokine secretion or surface receptor engagement [45]. For instance, IL-12 produced by 
APC was sufficient to activate iNKT cells in vivo, even without CD1d antigen presentation 
[45]. Moreover, iNKT cells express a wide range of surface receptors that are characteristics 
of natural killer cells such as NK1.1 (CD161 in human), NKG2D and NKp46 and that correlate 
with their functional activation and maturation status. More often, the TCR-mediated and 
the cytokine-dependent stimulations occur simultaneously and work in synergism [45]. 
Another feature they share with innate immune cells is that iNKT cells store huge amounts 
of cytokines in cytoplasmic granules. These vesicles can be quickly degranulated upon 
stimulation, leading to a massive and prompt immune response [49]. 
 
 
Figure 1.2 Conventional and non-conventional T cell subsets. Invariant natural killer T (iNKT) cells are 
a CD1d-restricted subset of T cells that express a semi-invariant T-cell receptor  together with markers 
of NK cells. Adapted from L Van Kaer, Nature Reviews in Immunology, 2005 [50]. 
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iNKT cells develop in the thymus following a differentiation pathway based on positive 
selection by thymocytes that conveys an antigen-experienced phenotype and a functional 
maturation status [49]. While some of them remain in the thymus as long-term residents 
exerting homeostatic functions [49], others egress from the thymus and reach peripheric 
lymphoid and non-lymphoid organs, thanks to their expression of chemokine and homing 
receptors [51]. Experiments with parabiotic mice showed that once in the periphery, most 
iNKT cells do not recirculate and become tissue-resident lymphocytes [52]. 
Murine iNKT cells have been well studied in spleen, intestine and liver where they represent 
2%, 1% an 40% of the total T cell population, respectevely [19]. Less is known about iNKT 
cell distribution in humans, but they appear to be slightly less abundant [49]. Nonetheless, 
considering their high similar specificity and their prompt and potent response, a 1% 
population has the potential to greatly influence the outcome of the tissue immune 
response at mucosal sites.  
As described in Section 1.5 for CD4+ T cells, also iNKT cells differentiate into several subsets 
with distinct functional activities. The subset of NKT1 resembles the one of Th1 for T helper 
cells. They express Tbet transcription factor which drives the production of IFNγ and TNF 
and they are mainly localized in liver, spleen, lungs and intestine [49]. Lymph nodes have 
been shown to be enriched in NKT17 cells, producing IL-17 and expressing RORγt 
transcription factor. Differently from Th2 cells, NKT2 are not expressing GATA3 
transcription factor so they are often tracked for their double negative expression of Tbet 
and RORγt, besides their secretion of IL-4 and IL-13 [49]. NKT2 are found in each organ at 
low frequencies under homeostatic conditions but can contribute to intestinal 
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inflammation in IBD patients [24]. More recently, the NKT10 subset has been described to 
exert regulatory functions through the production of  the tolerogenic IL-10 cytokine [53]. 
NKT10 are mainly localized in the adipose tissue [54]. Interestingly, murine experiments of 
adoptive transfer with iNKT cells derived from different organs showed that the 
determining factor for iNKT cell phenotype and functional activity is the surrounding 
environment rather than an intrinsic cell lineage definition [51], suggesting a functional 
plasticity also for iNKT cells. 
In addition to iNKT cells, there is another subset of CD1d restricted T cells, referred to as 
type 2 NKT cells, which have a more diverse T-cell receptor repertoire and do not recognize 
αGalCer. At least a subset of Type 2 NKT cells can be identified through sulfatide-loaded 
tetramers [22] 
 
1.7 Gut microbiota 
The intestinal tract represents the largest repertoire of microorganisms referred to as 
microbiota, a term that comprises a collection of bacteria, viruses and fungi [55]. The 
human body shelters 3.8×1013 bacterial cells, among which 1011 bacteria reside in the colon 
[56]. The number of bacterial cells is of the same order as the number of human cells [56]. 
As a result of this, the human host and the microorganisms inhabiting it are referred to as 
“superorganism” [55].  
The host-microbiota interactions have co-evolved leading to the commensalism of many 
bacteria species. Indeed, the host takes advantage of many ecological services exerted by 
the microbiota, including the maintenance of epithelial integrity [57], the harvesting of 
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nutrients and the protection against pathogens, such as Citrobacter rodentium [58] and 
Helicobacter hepaticus [59]. One of the mechanisms through which the gut microbiota 
prevents pathogen infection is the so called “colonization resistance” [60]. This concept 
dates back in the 1960s and illustrates the role of indigenous microbiota in antagonizing 
pathogens through (i) competition for the same ecological niches and (ii) potentiation of 
the mucosal barrier function [61].  
In the last decade the techniques used to study the microbiota have greatly improved due 
to the advent of culture-independent approaches that allow high throughput and low cost 
sequencing [62]. This started an enormous interest in this topic, as clearly illustrated by the 
16 000 citations found in PubMed upon “gut microbiota” search, 70% of which dated after 
the year 2000 [63]. 
Combined data obtained by two international consortium projects, i.e. the European 
MetaHit (metagenomics of the human intestinal tract) and the American Human 
Microbiota Project, provided substantial information on human-associated microbial 
repertoire [64], [65] . They identified 2172 bacterial species, classified in 12 phyla, of which 
93.5% belonged to Proteobacteria, Firmicutes, Actinobacteria and Bacteroidetes [55]. Most 
studies have utilized stool samples, however this provides an incomplete representation of 
the gut microbiota, since the composition of mucosa-associated microbes differs from the 
faecal one [66]. 
Moreover, it is becoming increasingly acknowledged that the sole description of microbial 
composition is of limited utility and a more detailed analysis of microbiota genome 
(microbiome) and metabolism is required. Indeed, the Human Microbiome Project 
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reconstructed the relative abundances of metabolic pathways in community metagenomes 
and coupled it with a metagenomic analysis of taxonomy [67]. Unlike microbial taxa, 
several pathways resulted to be ubiquitous among individuals, suggesting the existence of 
a high functional redundancy among different species [67]. 
The gut microbiota colonizes the gastrointestinal (GI) tract starting from the gestation 
period and then rapidly after birth. During the first years of life, the microbiota is constantly 
evolving in composition, increasing its diversity and typically resembling the gut microbiota 
of the mother [55]. In adulthood, the composition of the gut microbiota has been shown 
to be relatively stable. Adult individuals cluster in three main groups, called enterotypes, 
depending on the enrichment of three genera: Bacteroides (enterotype 1), Prevotella 
(enterotype 2) and Ruminococcus (enterotype 3) [68].  
Nonetheless, also the adult gut microbiota composition is subject to perturbations by life 
styles and events. For instance, a change in diet can dramatically impact on the microbiota. 
It has been shown that the microbiota is shaped by the availability of microbiota-accessible 
carbohydrates (MACs) that are found in dietary fibers. Administration of a low MAC diet to 
mice resulted in a drastic reduction in microbial diversity [69].  
Moreover, important modifications in gut microbiota composition can also be caused by 
the use of antibiotics [70], especially in early life [71], and by the existence of defined 
pathologies in the host [60]. This reflects the strict relationship between gut microbiota 
and the host immune system. 
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1.8 Interactions between the microbiota and the adaptive 
immune system 
Despite many intestinal bacteria developed a symbiotic relationship with the host, the 
proximity of the intestinal tissue with such a huge bacterial load leads to great health 
challenges. Thus, the mucosal immune system has evolved to restrain the microbiota while 
preserving the benefits deriving from host-microbiota association [72].  
To do so, several molecular mechanisms are in place to allow bacterial recognition by the 
host. Even in the presence of an intact epithelial barrier, microbial products and 
metabolites can be sensed by epithelial and lamina propria residing cells. The host 
recognizes microbial-associated molecular patterns (MAMPs) through pattern recognition 
receptors (PRRs). The best studied PRRs are the Toll-like receptors (TLRs), a family of 
transmembrane receptors recognizing external components of microorganisms. TLRs have 
been shown to play a crucial role in the maintenance of intestinal homeostasis as well as in 
the protection from epithelial injuries [73]. NOD-like receptors (NLRs) are another well-
known family of PRRs. They are cytoplasmic receptors that primarily sense bacterial 
MAMPs and they seem to be involved in Crohn’s disease pathogenesis, since a mutation in 
the NOD2 gene has been linked to genetic predisposition for this disease [74].  
A high frequency of T cells is found in mucosal tissues colonized by commensals, and this is 
especially true for the gastrointestinal tract. Indeed, many studies in which the gut 
microbiota was depleted using broad spectrum antibiotics or by maintaining mice colonies 
in germ free (GF) conditions, highlighted an impairment in T cell accumulation in the gut-
associated lymphoid tissue (GALT) [58], [59], [75].  
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In recent years many efforts have been dedicated on the characterization of defined 
microbial strains or products directly associated to specific T cell subset expansion and 
activation (Figure 1.3). The Segmented Filamentous Bacteria (SFB) present in 
conventionally raised mice from Taconic Farms, but not from Jackson Laboratories, was 
shown to be associated to Th17 cells. Its mono-colonization of GF mice turned out to be 
sufficient to induce IL-17 secreting CD4+ T helper cells [58]. The induction of Th17 cells by 
SFB resulted in protection from the infection of the intestinal pathogen Citrobacter 
rodentium. Following works showed that the adhesion of microbes to intestinal epithelial 
cells was critical for the induction of Th17 cells [76]. However, SFB or an equivalent family 
of adhesive bacteria failed to be identified in the human gut microbiota [77], posing 
impediments to the clinical translation of this finding.  
Moreover, commensals have been shown to control also the induction of immune-
modulatory responses. Remarkably, oral tolerance, the active suppression of immune 
responses against dietary antigens, is impaired in the absence of a healthy microbiota [78]. 
Consistently, GF mice colonization with a defined and benign mix of intestinal bacteria 
(Altered Schaedler Flora, ASF) specifically induced Treg expansion in the colonic lamina 
propria [75]. Furthermore, it has been described that a single bacterial metabolite 
(polysaccharide A, PSA) produced by Bacteroides fragilis could promote regulatory 
responses thus protecting mice from DSS-induced colitis [59]. This effect was achieved 
through the induction of IL-10 producing Treg cells. Moreover, also a mix of 46 Clostridium 
strains, particularly of clusters IV and XIV, promoted Treg expansion both in colon lamina 
propria and systemically [79]. These cells showed also a markedly suppressive phenotype, 
expressing high levels of IL-10 and CTLA-4, a key component of the immune checkpoint 
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[79]. The mechanism of Treg induction is still largely unknown, but the production of short 
chain fatty acids (SCFA) by Clostridia might be involved [80].  
SCFA are a family of metabolites produced from the fermentation of undigested complex 
carbohydrates and can serve as important energy source for both gut microbiota and the 
host epithelial surface [81]. Many studies tackled the role of these metabolites in 
modulating frequencies and function of FoxP3+ Treg cells [82], [83]. Moreover it has been 
shown that SCFA might be also sensed by APCs, such as dendritic cells and monocytes, 
inducing a downregulation of the antigen presentation machinery (both MHCII and co-
stimulatory molecules like CD80 and CD86), thus indirectly regulating T cell responses [84]. 
In addition, dendritic cell IL-12 production was inhibited in favor of IL-10 secretion upon 
SCFA stimulation, suggesting that they activate multiple immune pathways collectively 
aimed at the regulation of the inflammation [84]. The lack of SCFA has been linked to many 
human diseases, encompassing Type 2 diabetes and Inflammatory Bowel Disease [85]. The 
restoration of SCFA-producers in patients have been described as beneficial. To this 
purpose, they have recently suggested a dietary intervention on diabetic patients in order 
to promote the establishment of a core functional unit of SCFA-producing bacteria by 
modulating the availability of complex carbohydrates [86]. This approach resulted in a 
successful amelioration of patient clinical conditions and suggested a novel ecological 
approach for the manipulation of gut microbiota [86]. 
Non-conventional T cells, too, can interact with microbiota at mucosal surfaces. Recently, 
a skin commensal has been shown to be able to induce T cell homeostatic responses via 
non-classical MHC I molecules engagement [87]. 
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Indeed, the laboratories of R.S. Blumberg and M. Kronenberg provided groundbreaking 
evidences revealing the existence of mutual mechanisms of regulation between the 
intestinal microbiota and iNKT cells [88], [89]. Although these cells respond to some 
commensal bacterial antigens, the presence of the gut microbiota is not strictly required 
for their development in the thymus. Indeed, they have been shown to be present in GF 
mice [71], [90]. Peripheral iNKT cells have been shown to be reduced in numbers and to 
have a less activated phenotype in GF mice [71], [90]. Interestingly, though, the same cells 
isolated in the intestinal lamina propria were shown to be increased [71]. This observation 
pointed to a negative shaping of iNKT cell repertoire by commensal bacteria, an evidence 
confirmed also by the use of short term oral antibiotics administration [91] and in mice 
with a restricted flora enriched in Firmicutes [92]. 
The gut microbiota has been shown to regulate iNKT cell functions through multiple 
pathways. Firstly, the absence of commensal bacteria increases the production of CXCL16 
(the iNKT cell chemoattractant molecule) by intestinal epithelial cells through an epigenetic 
control of the cxcl16 gene locus [71]. More recently, the commensal Bacteroides fragilis 
has been recognized as the source of an α-galactosylceramide antigen (Bf1717) which binds 
the CD1d but, unlike αGalCer, fails to activate iNKT cells, thus limiting CD1d-dependent 
iNKT cell proliferation [93]. Moreover, gut microbiota has been shown also to indirectly 
affect intestinal iNKT cell pool by modulating the expansion of other T cell subsets [92]. 
Importantly, the iNKT cell numbers in GF mice could be normalized by colonizing neonatal 
mice with a healthy microbiota, though this was not possible in young adult mice [71]. This 
suggests that iNKT cells are subject to an immunologic imprint by early microbial exposure 
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possibly aimed at preventing hyperreactive inflammatory responses towards the 
commensal microbiota in the intestine. 
One possible interpretation of these observations, is that microbiota independent prenatal 
and neonatal iNKT cell development provides a first-line of defense at mucosal surfaces 
during early postnatal periods [88]. In this window of time, the host is at risk of intestinal 
infections because, on one hand, the unstable microbiota is not conferring a sufficient 
colonization resistance, and, on the other hand, the adaptive immune response is still 
immature and may not be able to confer protection against microbial pathogens. Later on 
during the host growth, iNKT cell activity at mucosal surfaces becomes less crucial because 
gut microbiota composition is less prone to modifications and the adaptive immune 
response has developed and is correctly in place. In fact, it has been proposed that in adults 
intestinal iNKT cell role in homeostasis becomes marginal, while instead they may 
importantly contribute to intestinal inflammation [88]. 
Interestingly, the gut microbiota- iNKT cells interaction is bidirectional. Interestingly, the 
gut microbiota- iNKT cells interaction is bidirectional. It has been recently shown that also 
NKT cells are impacting on microbial composition in the intestine [94]. Indeed, in CD1d 
deficient mice, bacterial colonization is favored due to an impairment in AMPs release by 
Paneth cells [94]. 
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Figure 1.3 Microbiota shaping of intestinal T cell subsets. Some of the many ways that intestinal 
microbiota shape host immunity are depicted. These includes microbiota inhibition of mucosal iNKT 
cell proliferation, SFB induction of Th17 lineage and Clostridia and B.fragilis triggering of Treg. 
Adapted from LV Hooper, D Littman, AJ MacPherson, Science, 2012 [72].  
 
 
1.9 Inflammatory Bowel Disease   
As the largest reservoir of effector CD4+ T cells and the site of the greatest secondary 
education of CD4+ T cells, the bowel is at constant risk of developing immune related 
diseases such as Inflammatory Bowel Diseases (IBD). IBD, including Ulcerative Colitis (UC) 
and Crohn’s Disease (CD), are a family of auto-immune chronic relapsing disorders 
characterized by pathologic inflammation of the gastrointestinal tract and epithelial injury 
[95]. While in UC patients the inflammation is restricted to the colon and has a continuous 
pattern starting from the rectum, CD has a preferential manifestation area in the terminal 
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ileum but can involve the whole digestive system and it is characterized by a discontinuous 
pattern of inflammation [96]. Moreover, CD inflammation is transmural, affecting all the 
layers of the intestinal wall, while UC patients have a superficial inflammation occurring in 
the mucosa and submucosa [97]. 
IBD occurs in genetically susceptible individuals and is considered a polygenic disorder, 
familial in the 5-10% of the population and sporadic for the remainder [95]. Studies on 
monozygotic twins demonstrated that there is phenotypic concordance in 50-75% of twins 
affected by CD, but only in 10-20% in those affected by UC, suggesting that heritability is 
less important in UC patients compared to CD ones [95]. The discordance in monozygotic 
twins and the occurrence of IBD in immigrants to high-prevalence Western countries, 
highlight the multifactorial nature of this family of disorders. However, the environmental 
factors involved in IBD pathogenesis are still poorly understood [95]. 
Genome wide association studies (GWAS) identified more than 240 genetic risk loci [98]. 
While some of them confirmed the role of already acknowledged immune-related 
pathways (IL-23, Th17, HLA/MHC), others previously unappreciated pathways such as 
autophagy and bacterial recognition (ATG16L1, NOD2) emerged from these analyses, 
underlying the importance of microbe-host interaction [99]. Interestingly, most genetic loci 
involved overlap between CD and UC [100]. 
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1.9.1 Physical intestinal barriers in IBD 
All the key components of the mucosal immune system that we described previously in this 
Chapter are markedly perturbed during IBD inflammation. Firstly, the epithelial barrier is 
dysfunctional, resulting in an increased intestinal permeability with the consequent 
translocation of luminal products, of both bacterial or dietary origin, into the lamina propria 
[96]. The main reason for epithelial barrier impairment is that tight junctions’ proteins are 
differentially expressed in IBD patients, thus rendering the epithelial seal leaky [97], [101]. 
The expression of TJs proteins is known to be greatly modulated by pro-inflammatory 
cytokines that, as it will be discussed later, are drastically enriched in the lamina propria of 
IBD patients. Secondly, also the mucus layers are greatly altered during intestinal 
inflammation [7]. Patients with active disease display the mucus that is more penetrable to 
bacteria. UC patients have been found to have reduced goblet cell numbers in the colon as 
well as a thinner mucus layer due to an altered glycosylation profile [101]. Moreover, GWAS 
identified mutations in the MUC1 and MUC4 genes as more associated to CD patients [102], 
[103]. In addition, CD patients with the autophagy pathway mutated in ATG16L1 gene, have 
been shown to have abnormal Paneth cells with dysfunctionality in granule assembly and 
anti-microbial proteins secretion [8]. 
 
1.9.2 Adaptive immunity in IBD 
Although an adaptive immune response is not strictly required for development of colitis 
in mice [104], it is undoubtedly a crucial player with the involvement of both bacterial-
specific B and T cells. Originally, the pathogenesis of CD and UC was thought to be 
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characterized by a functional dichotomy of Th1/17 versus Th2 abnormal responses, 
respectively. Recent studies and randomized clinical trials (RCTs) have questioned this idea 
[105]–[107]. 
The discoveries that IL-17 expression is increased in both CD and UC patients [108] and that 
IL-17 secreting CD4+ T helper cells, originating from CD161+ CD4+ precursors [109], are 
substantially infiltrating CD patient intestinal mucosa [110], have led to hypothesize that 
Th17 cells may actively contribute to CD pathogenesis [111]. This hypothesis has been 
challenged by the negative results of a clinical trial evaluating the efficacy of a monoclonal 
antibody against IL-17A in patients with luminal CD [106]. The recent understanding that 
Th17 cells do not represent a homogeneous entity but divide into at least two different 
subsets based on cytokine profile and pathogenicity, could provide an explanation for these 
apparently conflicting results. Classical Th17 cells, induced in presence of TGFβ and IL-6, 
have been found to possess regulatory activities, owing to the coproduction of IL-17 and 
IL-10 [39]. Alternative Th17 cells, on the opposite, are characterized by the concomitant 
production of IL-17 and inflammatory cytokines, including IFNγ, and have been found to 
mediate pathogenic activities in experimental models of inflammation [39]. Since then, 
different studies have corroborated the existence of a functional plasticity of Th17 cells 
towards the Th1 lineage, both in murine models and in human autoimmune diseases, 
including IBD [39]. At present, factors associated with pathogenicity of in vivo-
differentiated Th17 cells in the gut are yet to be fully elucidated. In this context, we and 
others suggested that IFNγ produced by in vivo [35] and in vitro-differentiated[35], [112] 
Th17 cells might exert a direct pathogenic role in  murine models of intestinal inflammation 
[35], [111] and in CD patients [35]. 
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Experiments of ex vivo stimulation of lamina propria mononuclear cells (LPMCs) showed 
that, in contrast to CD, UC-derived cells expressed lower levels of IFNγ in favor of IL-5 [113]. 
This observation fueled the idea that the T helper cell lineage involved in the pathogenesis 
of UC could be the Th2 one. Moreover, experimental murine models of chemically induced 
colitis (oxazolone-induced colitis) [114], corroborated by some studies involving UC 
patients [115], implicated a role for CD161+ IL-13-secreting NKT cells in the pathogenesis of 
UC. Interestingly, most of these CD1d reactive T cells were not iNKT, since they did not 
express the invariant Vα24-Ja18 TCR [115] and they were tracked by sulfatide-loaded 
tetramers [24]. However, the failure of a recent RCT aimed at the blockade of IL-13 
production in UC patients questioned the prominent role of this cytokine in the 
pathogenesis of UC [107]. Moreover, experimental evidences on human UC-derived LPMCs 
[105] and mouse models of oxazolone colitis performed in different genetic backgrounds 
[116], revealed that the intestinal inflammation in UC patients was characterized by Th1 
cytokine signature, as well. 
 
1.9.3 Gut microbiota in IBD 
One of the proposed mechanisms of IBD pathogenesis is an abnormal adaptive immune 
response against luminal microbiota [117], which results in the breakdown of the mucosal 
tolerance to enteric bacteria. Moreover, among all the IBD-associated risk factors, many 
are known to induce microbiota perturbations, i.e. mode of delivery (vaginal vs caesarean), 
milk feeding (breast vs artificial), antibiotics use, hygiene, diets [70]. Altogether, these 
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evidences suggest a strong association between intestinal inflammation and gut 
microbiota.  
Indeed, in the past years, many studies have revealed an alteration of the microbiota 
composition and function in IBD patients, defined as dysbiosis [118]–[122] (Figure 1.4). In 
contrast to a healthy microbiota which shows a great plasticity and the capacity to adapt 
to short-term perturbations going back to a pre-disturbance state when possible, the IBD 
associated dysbiotic microbiota manifest a reduced resilience [99]. 
The IBD-associated dysbiosis presents different features [99], [123]. Firstly, IBD patients are 
characterized by a decrease in bacterial species α diversity, a measurement of the 
ecological biodiversity of the microbial community [118], [120] (Figure 1.4). In this setting, 
the colonization resistance, namely the ability to outcompete pathogens, is impaired [60]. 
Accordingly, it has been shown that repeated antibiotics use in CD patients amplifies the 
state of dysbiosis and that this results in an aggravation of the disease severity  [120].  
 
Figure 1.4 Gut microbiota dysbiosi in IBD patients. 
IBD patients experience a shift in overall gut 
microbiota composition compared to healthy 
patients (upper panel) and a decrease in microbial 
α diversity (lower panel), measured with 
Shannon index. Adapted from F Imhann et 
al.,Gut, 2016. [117] 
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Secondly, dysbiosis can also be intended as the expansion of pathobionts, namely symbiont 
species that are able to promote pathology if specific genetic or environmental conditions 
are altered in the host [124]. While pathobionts are found only in low frequency in healthy 
hosts, they can overgrow in dysbiosis and contribute to the disease in susceptible hosts.  
In addition to pathobiont expansion, dysbiosis is often regarded as shifts in the overall 
microbial composition [99]. Since the advent of the sequencing technology for 
metagenomics analyses, many studies have addressed the microbiota composition of IBD 
patients, dealing with the intrinsic complexity created by the high variability among 
patients and with difficulties in using a proper healthy participant cohort [118]–[121]. A 
very elegant recent work tried to integrate the results of a considerably big case-control 
study with previous data [118]. The obtained consensus of overall microbial composition 
shift states that among IBD patients, CD ones experience a more marked dysbiosis 
compared to UC patients. Moreover, the phyla of Bacteroidetes and Proteobacteria were 
increased in both UC and CD patients, while Firmicutes was decreased only in UC. In 
contrast, Actinobacteria and Tenericutes were decreased in CD patients. Among the 
phylum Bacteroidetes, the order Bacteroidales was increased both in CD and UC compared 
to healthy controls, while the family Rikenellaceae and the genus Bacteroides were 
increased only in UC patients. Within the order Clostridiales of the Firmicutes phylum, CD 
patients experienced a decrease in families Christensenellaceae, Clostridiaceae and 
Ruminococcaceae. At lower taxonomic levels, also some species were observed to be 
significantly reduced in IBD patients, such as Faecalibacterium prausnitzii [125] and 
Roseburia intestinalis [119], [120]. 
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Apart from bacterial changes in composition and diversity, the IBD dysbiosis is also 
associated to modifications of functional metabolic activities. In dysbiotic conditions, 
microbial pathways for oxidative stress tolerance, immune evasion, metabolite uptake, 
amino acid and carbohydrate synthesis are upregulated [119]. 
Despite the huge amount of observational results generated by the latest case-control 
studies, it remains still elusive whether the link between microbiota dysbiosis and 
inflammation is causative [126]. Nonetheless, gut microbiota similarities in twins both 
concordant and discordant for IBD have been shown in several studies [126]. Furthermore, 
in a healthy individual cohort, the IBD risk score (based on the presence of genetic 
mutations in IBD risk loci) has been associated with a decrease in Roseburia spp [118], 
similarly to what happens in IBD patients. Collectively, these evidences demonstrate that a 
genetic trigger can be responsible for the microbial alteration even in the absence of 
inflammation, suggesting that the establishment of dysbiosis could occur before intestinal 
inflammation [126]. A clearer evidence of gut microbiota direct contribution to the 
development of intestinal inflammation comes from experimental preclinical studies. The 
transplantation of disease-associated but not healthy microbiota can transmit the 
pathology in a CD mouse model of ileitis [127]. In the same way, mice deficient in CD1d 
expression bear a dysbiotic pro-inflammatory microbiota that can trigger a basal 
inflammation when transferred in healthy mice [128]. 
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1.9.4 Therapeutic microbiota manipulation 
Since an alteration of intestinal bacteria is associated with development of IBD, the 
modulation of gut microbiota has become an active area of research. 
The use of antibiotics is the easiest way to impact on gut microbiota, thus, their use for IBD 
patients is of great interest. Antibiotics could act through a decrease in luminal bacterial 
load as well as through the selective targeting of pathobionts in favor of beneficial bacteria 
growth [70]. Nonetheless, as most of the commercially available antibiotics have a broad-
spectrum activity, they often impact not only on harmful bacteria, but also on beneficial 
ones. To overcome this absence of specificity, a recent study on murine models of colitis 
utilized a tungsten-based treatment to target an inflammation-associated enzyme of the 
family Enterobacteriaceae, thus showing an amelioration of colitis due to antibiotic-
independent precision editing of the gut microbiota [129]. Moreover, an important side 
effect of antibiotics treatment is the reduction in bacterial diversity, with the following 
impairment in colonization resistance microbiota properties [130]. For this reason, 
antibiotics treated IBD patients are at great risk of developing Clostridium difficile infection 
(CDI), the leading cause of infectious diarrhea in hospitalized patients [131]. Indeed, it has 
been demonstrated that the antibiotic driven microbiota depletion leads to a lack in 
primary bile acid processing in the colon. Since secondary bile acids can inhibit C. difficile 
growth by impairing the germination of its spores, their absence in antibiotic treated 
patients can promote C. difficile infection [70]. To avoid this risk, the clinical European and 
American guidelines (ECCO and ACOG respectively) do not recommend antibiotic 
treatment for IBD patients, despite their use resulted in a modest benefit when 
administered to active luminal CD patients and in prolonged maintenance of remission 
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[130]. However, antibiotic treatment remains highly recommended when the patient is at 
risk of infection as in case of abscesses and fistulas, or pouchitis [130].  
In addition, another approach to modulate microbiota composition that has been proposed 
for IBD patients is the dietary intervention. Indeed, dietary composition has been 
associated with changes in the composition of gut microbial populations [132]. A western 
style diet (WSD) enriched in saturated fats and simple carbohydrates but depleted in fibers 
has recently been shown to induce intestinal barrier defects via the reduction in 
Bifidobacteria [133]. Conversely, a semi vegetarian diet (i.e. milk and eggs allowed, fish 
once a week and meat once every two weeks), resulted in enhanced maintenance of 
remission in CD patients [134]. Indeed, a diet enriched in resistant starch or supplemented 
with prebiotics, allows for complex carbohydrates arrival to the large intestine where they 
can ferment into SCFAs, an important energy source for both gut microbiota and the host 
epithelium. Nonetheless, two RCTs aimed at testing the use of prebiotics, namely food 
ingredients that promote beneficial bacteria growth, in CD patients failed in detecting any 
amelioration in the disease [135]. However, studies about dietary intervention and 
prebiotics use are greatly limited by the inability to include placebo controls and by 
challenges in collecting accurate information from the patients.  
Probiotics are live organisms which provide a benefit to the host when administered in 
adequate amounts [136]. Many commensal bacteria have been tested in vitro and in vivo 
for their immunostimulatory functions or for their ability to protect the epithelial barrier. 
However, therapeutic use of such compounds requires caution, since it has been shown 
that in pathological conditions, such as colitis, they could amplify the inflammation [137]. 
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There is emerging evidence that multi-strain probiotic mixes are more efficient than single-
strain one and that their use in mild-to-moderate UC patients in combination with regular 
therapies is a valid approach to induce and maintain remission [138].  
 
The concept that a multi-strain probiotic holds a higher efficacy in restoring a healthy 
microbiota leads to take into consideration a radical way to interfere with microbiota: the 
Faecal Microbiota Transplantation (FMT). The FMT is a relatively novel therapeutic 
approach that encompasses the application of faecal microbiota from healthy donors into 
the intestine of dysbiotic patients. FMT practice has been shown to be highly effective in 
treating recurrent Clostridium difficile infection patients [139]. The characterizing dysbiosis 
of IBD patients makes them eligible as well for testing this clinical approach. Currently, 231 
RCTs investigating the safety and efficacy of FMT are registered and, among them, 38 are 
dealing with UC patients [140]. Nonetheless, so far, only three RCTs of phase II studies 
about FMT practice in UC patients have been completed and published [141]–[143]. The 
first study by Rossen et al. was carried out in The Netherlands and collected results from 
treatment of mild-to-moderate UC patients that were administered two doses of healthy 
FMT via nasoduodenal route of delivery. The Dutch team failed in detecting a significant 
improvement in attainment of remission (30% in FMT treated group, 20% in placebo 
group). Nonetheless patient responding to the treatment displayed an increased microbial 
diversity [141]. The second study held in Canada by Moayyedi et al. was conducted by 
treating patients with a total of 6 doses of FMT once a week supplied via enema. This time 
FMT treatment induced the achievement of the primary outcome of the study, namely the 
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remission of disease activity, in a percentage of patients statistically significantly higher 
compared to placebo group (24% vs 5%), suggesting that the route and frequency of 
administration play an important role [142]. Moreover, the placebo group of the Dutch 
study received an autologous FMT instead of a water enema, thus raising the doubt that 
this procedure could be considered as a true control placebo, since it likely results in a 
modification of the gut microbiota itself. The third study carried out by Paramsothy et al. 
in Australia introduced the use of multi-donor faecal material for the transplantation, with 
the aim to reduce the probability to receive ineffective donor stool [143]. Moreover, they 
prolonged the treatment and increased the frequency till 5 doses a week. They obtained a 
clinical remission in 27% of the treated patients versus the 8% of the water-placebo group 
(p = 0.021) and interestingly they showed that multi-donor preparations greatly increased 
the microbial diversity compared to individual donors [143]. Albeit the recent European 
Consensus Conference on FMT indicated the clinical practice of FMT only for CDI patients 
[131], the promising preliminary results on FMT efficacy in IBD patients recommend an 
accurate analysis on its application also for other pathologies. 
Despite these encouraging results from the clinical practice, only poor mechanistic 
evidence is present about the actual function of FMT. Given the strict network of 
interactions between gut microbiota and the host immune system, it would not be 
surprising to observe a direct modulation of immune cells in response to microbial 
manipulation during intestinal inflammation. Indeed, in a murine model of intestinal 
inflammation, FMT has been shown to ameliorate colitis through a downregulation of pro-
inflammatory cytokines and an increase in Treg cells [144]. 
40 
 
 
 
 
2 Aims  
 
The intestine has the challenge to preserve the integrity of the tissue while allowing pivotal 
exchanges with the external world [2]. To fulfill this task, the gut needs to maintain a 
balance between tolerance, required for food intake, and immunity, at risk of an 
overstimulation by the gut microbiota, including potential invading pathogens [3]. This 
delicate equilibrium is further demonstrated by the reciprocal functional shaping of the 
host mucosal immune system and of the gut microbiota throughout life [71], [145]. 
Here, we aim at investigating the functional interactions between the gut microbial 
community and the mucosal immune system during experimental and human intestinal 
inflammation and in the presence of microbial dysbiosis.  
Since patients suffering from Inflammatory Bowel Diseases manifest abnormal T cell 
responses associated to the recognition of dysbiotic commensal bacteria [117], to gain a 
better understanding of the pathogenic mechanisms responsible of intestinal inflammation 
development, we will specifically focus on: 
• Analyzing the effect of microbiota dysbiosis on intestinal T cell subsets activation; 
• Phenotypically and functionally characterizing T cell subsets activation in mouse 
models of intestinal inflammation and in IBD patients; 
• Unravelling the mechanism of action of therapeutic microbiota manipulation on the 
mucosal immune system during intestinal inflammation; 
• Studying the role of microbiota-driven regulation on iNKT cell functions and activity. 
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3 Materials and Methods 
 
3.1 Mice 
C57BL/6 mice (Charles River, IT) and CXCR6 EGFP/+ mice of 8-10 weeks of age were housed 
at the European Institute of Oncology (IEO) animal facility in SPF conditions. Animal 
procedures were approved by the Italian Ministry of Health (Auth. 127/15, 27/13, 913/16, 
415/17).  
Experimental groups of mice receiving the different treatments were kept in separated 
cages. Littermates of same sex and age were randomly assigned to the different 
experimental groups. 
CXCR6 EGFP/+ mice (B6.129P2-Cxcr6tm1Litt/J; IMSR_JAX: 005693) have C57BL/6 
background and were purchased as GFP/GFP from JAX, USA, and then were bred to 
heterozigosity with C57BL/6 mice). At weaning mice are screened for the presence of the 
GFP and WT alleles by multiplexed PCR on genomic DNA using GoTaq G2 Hot Start 
Polymerase (Promega) and primers listed in Table 3.1. 
 
Primer Allele Sequence 5' --> 3' 
oIMR0872 GFP AAG TTC ATC TGC ACC ACC G 
oIMR1416 MUT TCC TTG AAG AAG ATG GTG CG 
oIMR4077 WT Fw TAG TGG CTG TGT TCC TGC TG 
oIMR4078 WT Rev GGC AGC CGA TAT CCT TCA TA 
Table 3.1 Primer sequencing for CXCR6 EGFP/+ genotyping 
 
42 
 
 
 
 
The cycling protocol used is described in Table 3.2. 
 
Step # Temp °C Time Note 
1 94 3 min - 
2 94 30 sec - 
3 58 1 min - 
4 72 1 min repeat steps 2-4 for 35 cycles 
5 72 2 min - 
6 10 - Hold 
Table 3.2 Thermal cycler protocol used for CXCR6 EGFP/+ genotyping 
 
The assay amplifies a 173 bp band for the wild type allele and a 340 bp band for the GFP 
allele as shown in Figure 3.1. 
Figure 3.1 CXCR6 EGFP mice genotyping assay 
 
3.2 Murine experimental colitis models 
For the induction of DSS-induced acute and chronic colitis, mice were given 2% (w/v) 
dextran sodium sulphate (DSS, MW 40 kD; TdB Consultancy) in their drinking water for 7 
days followed by 2 days of recovery or for 3 cycles of 7 days of DSS followed by 14 days of 
water recovery, respectively. The weight curve was determined by weighing mice daily in 
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the acute models or twice a week for the chronic one. At sacrifice colons were collected, 
their length was measured and divided in portions to be fixed in 10% formalin for 
histological analyses, snap-frozen for RNA extraction and for lamina propria mononuclear 
cells (LPMC) immunophenotyping. Additionally, the luminal content was collected and 
immediately frozen. 
 
3.3 In vivo gut microbiota depletion 
To eliminate the whole gut microbiota, mice were administered with a whole spectrum 
antibiotic cocktail of neomycin (1g/L), ampicillin (1g/L), vancomycin (0.5 g/L) and 
metronidazole (1g/L) in their drinking water for at least 2 weeks.  
 
3.4 In vivo faecal microbiota transplantation 
The faecal microbiota transplantation (FMT) was performed through oral gavage of mucus 
(1st day) and faecal (2nd and 3rd days) preparations from healthy donor mice (normobiotic), 
DSS-treated mice (dysbiotic) or antibiotic treated mice (Figure 3.2). This protocol facilitates 
the engraftment of the mucus-associated bacteria that are also considered to be the ones 
that more likely interact with the host immune system. Mucus was scraped from the colons 
of the donor mice, diluted in PBS and administered to recipients at 1:1 ratio. Faeces were 
collected, diluted in PBS (50 mg/ml) and administered to recipients by oral gavage (10 
mg/mouse). To deplete distinct taxa of bacteria donor mice were treated with 
metronidazole (1g/L), vancomycin (1 g/L) or streptomycin (2g/L).  
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For in vivo IL10R blockade, mice were injected intraperitoneally with 250 µg InVivoMAb 
anti-mouse IL10R (BioXCell, clone 1B1.3A) daily for 4 days starting from one day before 
FMT treatment. 
 
Figure 3.2 Representative scheme of Faecal Microbiota Transplantation 
 
3.5 Microbiota identification by 16S rRNA gene- amplification, -
sequencing and data analysis 
The intestinal mucus was scraped from the colon, collected in TES buffer (50 mM Tris-HCl 
pH 7.5, 10 mM NaCl, 10 mM EDTA) and stored at -80°C. The faecal content was collected 
directly from the specimen and stored at at -80°C. The bacterial DNA was extracted with G 
NOME DNA isolation kit (MP Biomedicals) following the manufacturer’s instructions. The 
analyses of 16S rRNA amplification, sequencing and data analyses was performed by 
GenProBio s.r.l. (Parma, Italy). Partial 16S rRNA gene sequences were amplified using 
primer pair Probio_Uni and / Probio_Rev, targeting the V3 region of the 16S rRNA gene 
sequence [146] 16S rRNA gene sequencing was performed using a MiSeq (Illumina) at the 
DNA sequencing facility of GenProbio srl (www.genprobio.com) according to the protocol 
previously reported. Following sequencing, the obtained individual sequence reads were 
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filtered by the Illumina software to remove low quality and polyclonal sequences. All 
Illumina quality-approved, trimmed and filtered data were exported as .fastq files. The 
.fastq files were processed using a custom script based on the QIIME software suite. Paired-
end reads pairs were assembled to reconstruct the complete Probio_Uni / Probio_Rev 
amplicons. Quality control retained sequences with a length between 140 and 400 bp and 
mean sequence quality score >20 while sequences with homopolymers >7 bp and 
mismatched primers were omitted. In order to calculate downstream diversity measures 
(alpha and beta diversity indices, Unifrac analysis), 16S rRNA Operational Taxonomic Units 
(OTUs) were defined at ≥ 99 % sequence homology using uclust and OTUs with less than 10 
sequences were filtered. All reads were classified to the lowest possible taxonomic rank 
using QIIME and a reference dataset from the SILVA database. Biodiversity of the samples 
(alpha-diversity) were calculated with Chao1 and Shannon indexes. Similarities between 
samples (beta-diversity) were calculated by unweighted uniFrac. The range of similarities 
is calculated between the values 0 and 1.  
 
3.6 Metabolomic analyses by metabolite extraction, 
derivatization, identification with mass spectrometry and data 
analyses 
Metabolome extraction, purification and derivatization was carried out by Theoreo s.r.l. 
(Montecorvino Pugliano [SA], Italy) by means of the MetaboPrep kit according to the 
manufacturer’s instruction. 
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Two µL samples of the derivatized solution were injected into the GC-MS system (GC-2010 
Plus gas chromatograph coupled to a 2010 Plus single quadrupole mass spectrometer; 
Shimadzu Corp., Kyoto, Japan). Chromatographic separation was achieved with a 30 m 0.25 
mm CP-Sil 8 CB fused silica capillary GC column with 1.00 µm film thickness from Agilent 
(Agilent, J&W Scientific, Folsom, CA, USA), with helium as carrier gas. The initial oven 
temperature of 100 °C was maintained for 1 min and then raised by 4 °C/min to 320 °C with 
a further 4 min of hold time. The gas flow was set to obtain a constant linear velocity of 39 
cm/s and the split flow was set at 1:5. The mass spectrometer was operated in electron 
impact (70 eV) in full scan mode in the interval of 35-600 m/z with a scan velocity of 3333 
amu/sec and a solvent cut time of 4.5 minutes. The complete GC program duration was 60 
minutes. Untargeted metabolites were identified by comparing the mass spectrum of each 
peak with the NIST library collection (NIST, Gaithersburg, MD, USA). To identify metabolites 
identity, the linear index difference max tolerance was set at 10, while the minimum 
matching for the NIST library search was set at 85%. The chromatographic data for PLS-DA 
analysis were tabulated with one sample per row and one variable (metabolite) per 
column. According to MSI level 1 standard [147], the VIP putative metabolites identity was 
confirmed by means of an independent analytical standard analysis. The normalization 
procedures consisted of data transformation and scaling. Data transformation was made 
by generalized log transformation and data scaling by autoscaling (mean-centered and 
divided by standard deviation of each variable). Partial least square discriminant analysis 
(PLS-DA) [148] was performed on Internal Standard peak area [149] normalized 
chromatogram using R (Foundation for Statistical Computing, Vienna, Austria). Mean 
centering and unit variance scaling was applied for all analyses. Classes separation was 
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archived by PLS-DA, which is a supervised method that uses multivariate regression 
techniques to extract, via linear combinations of original variables (X), the information that 
can predict class membership (Y). PLS regression was performed using the plsr function 
included in the R pls package [150]. Classification and cross-validation was performed using 
the corresponding wrapper function included in the caret package [151]. A permutation 
test was performed to assess the significance of class discrimination. In each permutation, 
a PLS-DA model was built between the data (X) and the permuted class labels (Y) using the 
optimal number of components determined by cross validation for the model based on the 
original class assignment. Variable Importance in Projection (VIP) scores were calculated 
for each component. A VIP is a weighted sum of squares of the PLS loadings, taking into 
account the amount of explained Y-variation in each dimension.  
 
3.7 Histological analysis  
The histological analyses were performed in collaboration with the Pathology Unit of IRCCS 
Policlinico Hospital Milan. Tissue processing was performed with a LEICA PELORIS processor 
before paraffin embedding. Murine samples were embedded using an automated system 
(SAKURA Tissue-Tek). After Hematoxylin and Eosin staining, snapshots of histology were 
taken using an Aperio CS2 microscope with a scanning resolution of 50,000 pixels per inch 
(0.5 µm per pixel with 10x objective and 2.5 µm per pixel when scanning at 4x). Scoring of 
disease activity was performed according to the criteria described in Table 3.3 [91] 
(Appendix I).   
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 Criterion Definition Score  
Inflammatory 
cell infiltrate 
Severity (leukocyte density of lamina 
propria area infiltrated) 
No infiltrate 0 
 Minimal acute (<10%) 0.25 
 Mild chronic (10-25%, 
scattered neutrophils) 
0.5 
 Moderate chronic (26-50%) 0.75 
 Marked (>51%, dense 
infiltrate) 
1 
Extent (expansion of leukocyte 
infiltration) 
Mucosal 0.5 
 Mucosal and submucosal 0.75 
Epithelial 
changes 
Hyperplasia (increase in epithelial 
cell numbers in longitudinal crypts, 
visible as crypt elongation) 
No hyperplasia 0 
  Minimal (<25%) 0.25 
  Mild (26-35%) 0.5 
  Moderate (36-50%, mitoses in 
the upper third of the crypt 
epithelium) 
0.75 
  Marked (>51%, mitoses in 
crypt epithelium distant from 
crypt base) 
1 
 Goblet cell loss (relative to baseline 
goblet cell numbers per crypt) 
No loss 0 
  Minimal (<25%) 0.25 
  Mild (26-35%) 0.5 
  Moderate (36-50%) 0.75 
  Marked (>51%) 1 
Mucosal 
architecture 
Ulceration (epithelial defect reaching 
beyond muscolaris mucosae) 
No ulcers 0 
 Ulcers 0.25 
 Granulation tissue (connective tissue 
new capillaries, surrounded by 
infiltrating cells, hypertrophic areas) 
No granulation tissue 0 
 Granulation tissue 0.25 
 Mucosal thickness and crypt depth No thickening 0 
  Thickening 0.5 
 Glandular rarefaction No rarefaction 0 
  Rarefaction 0.5 
 Dysplasia No dysplasia 0 
  Dysplasia 0.5 
  MAX SCORE 6 
 
Table 3.3 Scoring scheme for histological evaluation of intestinal inflammation 
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3.8 Quantitative reverse transcription PCR (RT-qPCR) of tissue 
mRNA 
Colonic tissues were homogenized in 500 µl TRIzol (Invitrogen) and then RNA extraction 
was performed adding 100 μl of chloroform, precipitating the aqueous phase with 300 μl 
of 70% ethanol and purifying RNA with Quick-RNA MiniPrep (ZymoResearch) according to 
manufacturer’s specifications. cDNAs were generated from 1µg of total RNA with 
EasyScript PlusTM cDNA Synthesis kit (abm). Gene expression levels were evaluated by qPCR 
on 10ng cDNA using BrightGreen 2X qPCR Mastermix (abm) and normalizing to the 
housekeeping gene (Rpl32 for mouse and Gapdh for human) expression. The primer 
sequences are collected in Table 3.1. 
 
Primer Species Forward Reverse bp Vendor 
CXCL16 Mouse AGCGCAAAGAGTGTGGA GGTTGGGTGTGCTCT 193 SIGMA 
CXCR6 Mouse CCTTTTTGGGCCTATGCA ATGCCTCGAAGAGTT 71 SIGMA 
MCP-1 Mouse CAAGATGATCCCAATGA GGTTCCGATCCAGGT 161 SIGMA 
CXCL10 Mouse CGCTGCAACTGCCATCCA CCGGATTCAGACATC 148 SIGMA 
TNF Mouse TCTTCTCATTCCTGCTTG CACTTGGTGGTTTGCT 200 SIGMA 
IL6 Mouse CTCTGGGAAATCGTGGA GCAAGTGCATCATCG 77 SIGMA 
IL12 Mouse CCTGCTGAAGACCACAG AGCTCCCTCTTGTTGT 200 SIGMA 
Muc1 Mouse TACCCTACCTACCACACTCACG CTGCTACTGCCATTACCTGC 95 SIGMA 
Muc2 Mouse GTGTGGGACCTGACAATGTG TTGCCACCAGAACATTTCTTT 124 SIGMA 
Muc3 Mouse CTTCCAGCCTTCCCTAAACC TCCACAGATCCATGCAAAAC 119 SIGMA 
Muc4 Mouse GAGAGTTCCCTGGCTGTGTC GGACATGGGTGTCTGTGTTG 101 SIGMA 
CXCL16 Human AGCGCAAAGAGTGTGGA GGTTGGGTGTGCTCT 193 SIGMA 
CXCR6 Human CCTTTTTGGGCCTATGCA ATGCCTCGAAGAGTT 71 SIGMA 
MCP-1 Human CAAGATGATCCCAATGA GGTTCCGATCCAGGT 161 SIGMA 
CXCL10 Human CGCTGCAACTGCCATCCA CCGGATTCAGACATC 148 SIGMA 
TNF Human TCTTCTCATTCCTGCTTG CACTTGGTGGTTTGCT 200 SIGMA 
IL6 Human CTCTGGGAAATCGTGGA GCAAGTGCATCATCG 77 SIGMA 
Primer  Cat no. Vendor 
IL17a Mouse QT00103278 Qiagen 
IFNg Mouse QT01038821 Qiagen 
IL10 Mouse QT00106169 Qiagen 
IL23 Mouse QT01663613 Qiagen 
IL22 Mouse QT00128324 Qiagen 
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Rpl32 Mouse QT00131992 Qiagen 
Tjp1 Mouse QT00493899 Qiagen 
Camp1 Mouse QT00241003 Qiagen 
S100A8 Mouse QT00250264 Qiagen 
DEFb3 Mouse QT00265517 Qiagen 
IL1b Mouse QT010483555 Qiagen 
IL17 Human QT00009233   Qiagen 
IFNg Human QT00000525   Qiagen 
Gapdh Human QT00079247   Qiagen 
 
Table 3.4 qPCR primers 
 
3.9 Tissue ELISA of murine IL-10 
Colonic tissues were homogenized in 300 µl RIPA Buffer (Cell Signaling Technology) 
supplemented with Phosphatase inhibitors (Sigma) and Protease inhibitors (Complete Ultra 
tablets, Roche). The samples were then incubated at 4°C for 30 minutes under slow rotation 
and then centrifuged at 13000 rpm for 15 minutes at 4°C. The supernatant was quantified 
at the NanoDrop with Bradford Assay (BioRad). mIIL-10 was measured on 6.25 µg of lysate 
using the ELISA assay (Purified anti-mouse IL-10 and Biotin anti-mouse IL10, Biolegend) 
performed following manufacturer’s instructions. 
 
3.10 Faecal Bacteria Plating 
One faecal pellet from each mouse was smashed, filtered with 100 µm nylon cell strainer 
and resuspended in 1 mL of sterile PBS. 200 µL were then plated on Chocolate II Agar plates 
(BD) and grown at 37°C under aerobic conditions overnight or in anaerobic conditions for 
48 hours. 
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3.11 Murine Cell isolation 
For lamina propria mononuclear cell (LPMC) isolation, the colons were cut open, washed 
in PBS and then incubated in RPMI supplemented with 1 mM EDTA at 37°C for 30 minutes 
to detach the epithelial layer. The tissue was mechanically dissociated with GentleMACSTM 
(Miltenyi) and then serially smashed and filtered on a metal strainer first, and then with 
100 µm and 70 µm nylon cell strainers. The LPMC were then counted and stained. In some 
experiments after isolation, cells were re-stimulated ex-vivo for 3 hours with 0.1μM PMA 
(Sigma), 1μg/ml Ionomycin (Sigma-Aldrich) and 10μg/ml Brefeldin A (Sigma).  
 
3.12 Flow cytometry 
Human and murine cells were stained with combinations of directly conjugated antibodies 
as specified in Table 3.5, all sourced from BD, eBioscience, Biolegend or Tonbo. 
 
Marker Reactivity to Clone Vendor 
mCD1d:PBS57 Tet Mouse  Gift from NIH Tet facility 
CD45.2 Mouse 104 Biolegend 
CD3 Mouse 17A2 BD 
CD8α Mouse 53-6.7 eBioscience 
CD4 Mouse GK1.5 BD 
CD11c Mouse HL3 BD 
CD19 Mouse 1D3 BD 
CD11b Mouse M1/70 BD 
F4/80 Mouse BM8 Biolegend 
Ly6g Mouse 1A8 Biolegend 
Ly6c Mouse AL-21 eBioscience 
MHC-II Mouse M5/114.15.2 eBioscience 
Ki67 Mouse 16A8 Biolegend 
CD69 Mouse H1.2F3 BD 
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Ter119 Mouse TER-119 BD 
TCR α/β Mouse H57.597 BD 
TCR γ/δ Mouse UC713B5 Biolegend 
CD90 Mouse 53-2.1 BD 
CD117 Mouse 2B8 BD 
CD127 Mouse A7R34 Biolegend 
Nkp46 Mouse 29A1.4 BD 
RorγT Mouse AFKJS9 eBioscience 
ST-2 Mouse DIH9 Biolegend 
CD25 Mouse PC61 BD 
FoxP3 Mouse FJK-16s eBioscience 
IFNγ Mouse XMG1.2 BD 
IL10 Mouse JE65-16E3 BD 
IL22 Mouse Poly5164 Biolegend 
IL17A Mouse TC11-18H10.1 Biolegend 
IL13 Mouse eBio13A eBioscience 
TNF Mouse MP6-XT22 Biolegend 
Zombie Dye   Biolegend  
Zo-1 Mouse ZO1-1A12 Invitrogen 
hCD1d:PBS57 Tet Human  Gift from NIH Tet facility 
CD3 Human OKT3 Tonbo 
CD4 Human RPA-T4 Tonbo 
CD8α Human OKT8 Tonbo 
CD25 Human BC96 BD 
CD11c Human B-ly6 BD 
CD19 Human HIB19 BD 
IL17A Human BL168 BD 
IFNγ Human B27 BD 
TNF Human Mab11 R&D Systems 
IL13 Human 142928 Biolegend 
Anti-CD1d Human CD1d42 BD 
Anti-IFNγ Human NIB42 eBioscience 
Anti-TNF Human Mab1 eBioscience 
Anti-IL17 Human eBio64CAP17 eBioscience 
Anti-IL13 Human JES10-5A8 Biolegend 
Table 3.5 Antibodies and FACS reagents 
 
iNKT cells were identified by CXCR6 EGFP expression or by m/hCD1d:PBS57 Tetramer (NIH 
Tetramer core facility) staining. Prior staining, the Fcγ-receptors were blocked with anti-
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CD16/32 mAb (10g/ml). Murine and human tetramers were then incubated at 4°C for 30 
minutes with fresh cells at the concentration of, respectively, 0.1 µl/ 3x106 cells for murine 
cells or 0.2 µl/ 3x106 cells for human ones. The gating strategy to identify murine and 
human iNKT cells are described respectively in Figure 3.3 and Figure 3.4.  Intracellular 
cytokines were detected after stimulation of cells for 3 hours with 0.1μM PMA (Sigma), 
1μg/ml Ionomycin (Sigma-Aldrich) and 10μg/ml Brefeldin A (Sigma). Cells were fixed and 
permeabilized with Cytofix/Cytoperm (BD) before the addition of the antibodies detecting 
the cytokine released. Intranuclear transcription factors were detected after fixation and 
permealisation with Foxp3/Transcription Factor Staining Buffer Set (eBioscience™). 
Multiplexing analysis of cytokines in supernatants collected after in vitro stimulation was 
performed with a Cytokine Bead Array (CBA, BD), according to manufacturer’s protocol. 
Samples were analyzed by FACSCanto or FACSCelesta flow cytometer (BD), gated to 
exclude non-viable cells on the basis of light scatter. Data were analyzed using FlowJo 
software (BD).  
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Figure 3.3 Gating strategy for tracking murine iNKT cells (A) Forward and Side Scatter of colonic LPMC 
gate indicates living lymphocytes (B) Doublets-excluding gate (C) Epithelial cell-excluding gate based 
on CD45.2 expression. (D) Lineage (CD19, CD11c, CD11b)-excluding gate. (E) CD3 expression and 
CXCR6EGFP (F) mCD1d:PBS57 Tet staining on gated CD3+ EGFP+ cells confirms that 93% of EGFP+ cells 
are iNKT cells. (G) mCD1d:PBS57 Tet staining on gated CD3+EGFP-  cells. 
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Figure 3.4 Gating strategy for tracking human iNKT cells (A) From left, Forward and Side Scatter to 
identify lymphocytes and CD3/hCD1d:PBS57 tetramer expression. (B) Dot plots indicate iNKT cells 
staining with unloaded (left panels) or PBS57-loaded hCD1d Tetramer. 
 
3.13 In vitro murine intestinal cell activation assay 
Colonic lamina propria and mesenteric lymph node leukocytes were collected from 
untreated mice. 2×106 cells were plated and exposed to 0.05 mg of bacteria (wet weight) 
derived from faeces of untreated, DSS-treated or FMT-treated mice at the time of sacrifice. 
Gentamycin (50 µg/ml) and a cocktail of antibiotics (P/S) were added after 2 hours of 
incubation. The cells were left in culture for 96hrs. In some experiments, anti-MHCII 
blocking antibody (clone M5/114.15.2, TONBO) was added at a final concentration of 10 
µg/ml. At the end of the experiment cells were analysed by flow cytometry. Their viability 
was checked with Zombie Yellow™ Fixable Viability Kit (Biolegend). 
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3.14 Human Subjects 
Buffy-coated blood (HD, n=15, IBD n=5) and intestinal specimens of UC patients (n=16), CD 
patients (n=24), and patients undergoing intestinal surgical resection for pathologies 
unrelated to IBD, including diverticular disease and intestinal tumors (n=27) were obtained 
from the IRCCS Policlinico Ospedale Maggiore, Milan, Italy. The clinical characteristics and 
concomitant therapies of IBD patients are summarized in Table  3.6. The Institutional 
Review Board approved the study (permission ref. no. EA1/107/10) and informed consent 
was obtained from the subjects involved in the study. 
Clinical parameter 
Healthy 
controls n=27 
Ulcerative 
Colitis 
n=16 
Crohn’s disease 
n=24 
Male/Female, (n) 14 / 13 9 / 7 12 / 12 
Age at enrolment, 
(mean ± SD, yr)  
69.5 (± 12.3) 40.75 (± 13.3) 39.61 (± 7.4) 
Disease duration,  
(mean ± SD, yr)  
- 8,8 (± 4.8) 10.5 (± 6.2) 
Smoking status, 
(yes/no/ex) 
- 2/13/1 3/19/2 
Crohn’s disease, (n)    
L1 ileal - - 10 
L2 colonic - - 3 
L3 ileocolonic - - 11 
L4 upper - - 0 
B1 (no strict/no penetr) - - 6 
B2 (stricturing) - - 13 
B3 (penetrating) - -    5 
Ulcerative Colitis, n    
E1 proctitis -   1 - 
E2 left-sided - 11 - 
E3 pancolitis - 4 - 
Concomitant therapy  
at enrolment 
   
No therapy, (n) - 7 15 
Antibiotics, (n) - 0 1 
Mesalamine, (n) - 6 3 
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Thiopurines, (n) - - 5 
Corticosteroids, (n) - 3 2 
Anti-TNF, (n) - - 2 
  
Table  3.6 Patients description 
 
3.15 Human primary cell isolation 
Human peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque 
gradient (Sigma-Aldrich). Human LPMC were isolated as previously described [111]. Firstly, 
the tissue was resected, and the mucosa separated from the submucosa with forceps and 
surgical scissors. The intestinal mucosa was freed of mucus with a pretreatment of 15 
minutes at RT with dithiothreitol (DTT, 0.1 mmol/L, Sigma) and then washed with 3 cycles 
of 5 minutes with HBSS supplemented with Penicillin/Streptomycin (Gibco, Life 
Technology) and Gentamycin (Roche). To detach the epithelial layer the mucosa was then 
minced with scalpels and incubated in EDTA (1 mmol/L, Sigma) at RT (3 cycles of 50 
minutes). After three washes with HBSS supplemented with antibiotics the mucosa was 
incubated with collagenase D to digest the extracellular matrix (400 U/ml, Worthington 
Biochemical Corporation, Lakewood, NJ) o/n at 37°C and 5% CO2.  The cell suspension was 
then filtered with 100 µm nylon strainer and centrifuged at 1930 rpm for 10 minutes at RT.  
The cell suspension was then separated with a Percoll (Sigma) gradient (100%, 60%, 40% 
and 30%) at 1930 rpm for 30 minutes at RT. Lamina Propria Mononuclear Cells (LPMC) were 
then collected between the 60% and 40% layers, washed twice with PBS supplemented 
with antibiotics and then cultured in complete RPMI 1640 medium.  
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3.16 Intestinal iNKT cell lines and clone generation 
The population of CD45+CD3+ CD1d:PBS57Tet+  cells was sorted with FACSAria (BD) from 
total LPMC or PBMC. For the generation of human iNKT cell lines, sorted iNKT cells were 
expanded in vitro for two weeks in the presence of irradiated peripheral blood feeders 
(5x105/mL), hIL2 (100 U/ml, Proleukin) and PHA (1 µg/ml, Remel™).  
iNKT cell clones were generated via cloning by limiting dilution according to the protocol 
described in [152]. Briefly, the sorted iNKT cells were resuspended at three serial dilution 
in order to plate them at 5 cells/well, 1 cell/well  and 0.2 cell/well in 96 well plates. The first 
dilution resulted in a positive control as the majority of the wells showed growing cells. The 
plating efficiency was estimated by counting the number of negative wells and only the 
cells grown from the dilutions with a negative growth rate lower than 37% were considered 
as clones [152].  
Both iNKT cell lines and clones were then re-stimulated with irradiated feeder cells 
(5x105/mL), PHA (1 µg/ml, Remel™) and hIL-2 (100 U/ml, Proleukin) every 21 days. 
 
3.17 Human iNKT-cell in vitro stimulation 
Polycolonal iNKT cell stimulation was performed with 0.1 μM PMA and 1 μg/ml ionomycin 
(Sigma-Aldrich). Neutralizing antibodies to CD1d (BD) were used at the concentration of 10 
μg/ml.  
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For antigen specific stimulation, 5x104 antigen presenting cells (monocytes derived 
Dendritic cells or CD45+HLA-DR+ intestinal LPMC) were plated in each well at 1:1 ratio with 
human iNKT cells. Sonicated αGalCer was used at 40 ng/mL.  
For bacteria stimulation assays, purified bacterial strains (AIEC LF82 and S.Thyphymurium) 
underwent cycles of heat inactivation and freezing/thawing before being serially diluted 
starting from 5x106 CFU/well (100:1 bacteria:APC) to 5x105/well (1:1 bacteria:APC). The 
isolates of patient mucosa-associated microbiota were normalized according to their 
protein content (Pierce BCA Protein Assay kit, Thermo Fisher). After 36 hours T cell 
activation was estimated by measuring cytokine released in culture supernatants by ELISA 
assays, Cytometric Bead Array (BD) or intracellular staining. 
 
3.18 Measurement of trans-epithelial electrical resistance (TEER)  
The intestinal epithelial cell line Caco-2 was sourced from the American Type Culture 
Collection (ATCC) and cultured in DMEM supplemented with 20% FCS, 2MM L-glutamine, 
1mM sodium pyruvate, 0.1 mM non-essential amino acids (NEAA) and 
penicillin/streptomycin.  The cells were split three times a week. For TEER measurement 
the cells at passage 10-30 were plated at 15x103 cells/well on polyester permeable 
Transwell-clear inserts (6.5-mm diameter, 0.4-mm pore size, Corning®) and grown for 5‒7 
days, until ΔTEER >300 Ω*cm2 (Millicell-ERS Volt-Ohm Meter Millipore, Bedford, MA). 
The supernatants collected from intestinal CD4+ T cell clones, stimulated for 3 hours with 
PMA/ionomycin in Caco-2 medium, in the presence or absence of neutralizing Ab (anti- 
human -IFNγ, -IL-17A, -TNF (eBioscience), -IL13 (Biolegend) at concentration of 20 µg/ml 
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for anti-IFNγ and 10 µg/ml for the others) were applied in the lower transwell chamber.  
Measurements were carried out at the beginning of the assay, after 2 hours, after 16 hours 
and then every 2 hours until 26 hours after stimulation. The ohmic resistance of a blank 
(culture insert without cells) was measured in parallel. To obtain the sample resistance, the 
blank value was subtracted from the total resistance of the sample. The final unit area 
resistance (Ω*cm2) was calculated by multiplying the sample resistance by the effective 
area of the membrane. For comparison among treatments with different clones, TEER was 
normalized to the supernatant of each unstimulated clone.  
 
3.19 Fluorescence in situ hybridization (FISH) 
Formalin fixed paraffin embedded tissues are sectioned 5 m thickness. The probes (EUB1, 
EUB2, EUB3) used are designed to specifically target different regions of the 16S rRNA. All 
the probes are manufactured by SIGMA and labelled with Alexa488. Probes are applied to 
slides at a concentration of 5 ng/l in prewarmed hybridization buffer (0.9 M NaCl, 20 mM 
Tris pH 7.4, 0.01% SDS). Slides are incubated over night at 50°C in a humid chamber and 
washed at 50°C in pre-warmed washing buffer (0.9 M NaCl, 20 mM Tris pH 7.4). The slides 
are counterstained with DAPI. Confocal images are acquired through HCX PL APO 40X (NA 
1.25) oil immersion objective. The probes sequences are collected in Sup Tab.4. 
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3.20 Statistics 
Statistical analysis was performed with GraphPad Prism 5 (GraphPad Software). Statistical 
significance was calculated using a Mann Whitney test for comparison within two groups 
or Kruskal-Wallis test with Dunn’s multiple comparison correction within more than two 
groups. P < 0.05 (*), P < 0.01 (**) P < 0.001 (***) were regarded as statistically significant. 
Outliers were detected with Grubb’s test.  
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4 Results I 
 
Several evidences suggest that functional activation of immune cell populations in the 
lamina propria might be secondary to the recognition of an altered (dysbiotic) microbiota 
[153]. Nonetheless, it is currently unclear if any type of intestinal dysbiosis might be equally 
capable to trigger mucosal immune cells activation. 
Indeed, the disruption of the intestinal barrier and the following translocation of luminal 
bacteria and metabolites in the lamina propria are two key events in the aetiology of 
intestinal inflammation and colitis [154],[95].  
To study the mechanisms leading to the activation of immune cell populations in the 
intestinal mucosa in the presence of a microbial altered composition, we adopted two 
different models of dysbiosis induction, i.e. by Dextran Sodium Sulphate (DSS) or by broad-
spectrum antibiotics administration. 
Antibiotic-induced dysbiosis was obtained by treating for two weeks mice with broad- 
spectrum antibiotics (vancomycin, metronidazole, ampicillin, neomycin) in their drinking 
water, while DSS-induced dysbiosis was generated by administering DSS for one week, 
according to the acute colitis model [155].  
Both experimental settings are characterized by a relevant alteration in the microbiota 
composition, nonetheless they show peculiar differences, including the presence or 
absence of inflammation, of epithelial damage and of bacterial translocation. 
At the end of the treatments, colonic immune cells were analyzed, with a specific focus on 
conventional CD4+ T cells and unconventional iNKT cell phenotype and functions. 
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Since iNKT cells are scarcely present in mucosa-associated lymphoid tissues [20], we took 
advantage of the CXCR6 EGFP/+ reporter mice to faithfully track them in the intestine. As 
reported in Figure 3.3, mCD1d:PBS57 Tet staining on gated CD3+ CXCR6+ cells confirms that 
93% of CXCR6EGFP+ cells are iNKT cells. 
 
4.1 DSS-induced dysbiosis 
4.1.1 DSS induces intestinal inflammation and CD4+ and iNKT cells colonic 
accumulation 
DSS is a sulfated polysaccaride that is directly causing colonic epithelial toxicity and 
intestinal barrier dysfunction [156].  
DSS administration induced a strong intestinal inflammatory response, characterized by 
weight loss (Figure 4.1A), colon shortening (Figure 4.1B) and by histological signs of colonic 
inflammation (Figure 4.1C-D). These colonic tissues are characterized by epithelial changes 
including epithelial hyperplasia visible as crypt elongation and goblet cell loss, tissue 
architecture modifications such as ulcers and mucosal thickening, and by a marked immune 
cell infiltration [157], (Appendix I and Figure 4.1D). The extent of inflammation is also well 
documented by the expression of a broad array of inflammatory genes such as tnf, il17a, 
ifng, il23 and il12 Figure 4.1D) and chemokines associated to iNKT cell recruitment (Figure 
4.1F). 
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Figure 4.1 DSS induces acute intestinal inflammation. Acute experimental colitis was induced in 
CXCR6-EGFP/+ mice by DSS administration in drinking water. (A) Weight loss, (B) colon length and 
(C) histological score were compared in mice treated with DSS (black box) or water (white box). (D) 
Colonic expression levels of tnf, il17a, ifng, il23, il12, il10, Il22, il6, mcp-1, cxcl10 in untreated (white 
bars) and DSS-treated (black bars) mice by qPCR. (E) Colonic expression levels of cxcl16 and cxcr6 in 
untreated (white bars) and DSS-treated (black bars) mice by qPCR. Statistical significance was 
calculated using a Mann Whitney test for comparison within two groups. P < 0.05 (*), P < 0.01 (**), 
P < 0.001 (***) were regarded as statistically significant. Outliers were detected with Grubb’s test. 
 
Albeit DSS-induced intestinal inflammation model is known to be principally driven by the 
recruitment of innate immune cells, i.e. neutrophils and macrophages [156], we 
hypothesized that the translocation of luminal antigens into the lamina propria could also 
trigger the accumulation of T lymphocytes. We performed flow cytometric analysis of 
colonic lamina propria mononuclear cells (LPMC) comparing DSS-treated (DSS) and 
untreated (H2O) mice. DSS-induced inflammation was associated with the accumulation of 
both CD4+ T cells and CXCR6+ iNKT cells ( 93% of which were also mCD1d:PBS57 Tetramer+,  
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Figure 3.3) in the colonic mucosa (Figure 4.2A-B). This corresponded to an increased 
colonic expression of both CXCR6 and CXCL16 (CXCR6 ligand, Figure 4.1D), thus confirming 
previously published data [71]. 
 
 
Figure 4.2 T cells infiltrate the inflamed colonic mucosa. CD4+ T cells (A, CD45+lin-CD3+EGFP-CD4+) and 
iNKT cells (B, CD45+lin-CD3+ EGFP+) representative dot plots, frequency among CD3+ T cells and 
absolute numbers in colon of DSS-treated (black box) or controls (white box). Statistical significance 
was calculated using a Mann Whitney test for comparison within two groups. P < 0.05 (*), P < 0.01 
(**) were regarded as statistically significant. Outliers were detected with Grubb’s test. 
 
Having observed that CD4+ T and iNKT cells were associated with DSS- induced intestinal 
inflammation, we analyzed their ability to exert pro- or anti- inflammatory functions. We 
performed intracellular cytokine stainings of colonic LPMC. Interestingly, upon DSS 
treatment the production of the tolerogenic IL-10, the main player of the regulation and 
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resolution of the inflammation, was shut down both in CD4+ T and iNKT cells (Figure 4.3). 
During intestinal inflammation, the colonic CD4+ T helper cells were producing higher levels 
of IFNγ and IL-17 cytokines compared to untreated controls (Figure 4.3A). Collectively, in 
DSS-induced acute intestinal inflammation the T cell population displays a Th1/Th17 
cytokine profile, consistently to what described in Inflammatory Bowel Disease (IBD) 
patients [96].  
 
 
Figure 4.3 iNKT and CD4+ T cells exhibit a pro-inflammatory profile during acute intestinal inflammation 
in CXCR6 EGFP mice. Intracellular stainings of cytokine production by CD4+ T cells (A) and iNKT cells (B) 
in DSS-treated and untreated mice. Statistical significance was calculated using a Mann Whitney test 
for comparison within two groups. P < 0.05 (*), P < 0.001 (***) were regarded as statistically 
significant. Outliers were detected with Grubb’s test. 
 
Taken together, these data suggest that CXCR6 EGFP/+ reporter mice are susceptible to 
DSS-induced colitis and can be used as a valuable tool to track and study intestinal T cell 
subset, including the rare population of iNKT cells. 
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4.1.2 Gut microbiota composition is altered during DSS-induced colitis 
Since during DSS-induced colitis the epithelial barrier is disrupted, and microbial 
components have been indicated as possible triggers of immune activation in the gut [153], 
we considered important to evaluate if changes in the colonic bacterial population might 
have occurred upon DSS treatment. To do so, faecal samples of DSS-treated and untreated 
mice were collected and subjected to microbiome profiling using 16S rRNA gene 
sequencing on the Illumina MiSeq platform. An unweighted UniFrac-based comparison of 
the microbiota was performed. Principle component analysis (PCoA) differentiated colitic 
mice from healthy controls (Figure 4.4A). Similarly, the microbiota isolated from DSS-
treated mice showed a lower α-diversity when compared to untreated mice microbiota, as 
reflected by the Chao1 and Shannon indexes (Figure 4.4B). A more detailed phylogenetic 
analysis of the taxonomic composition of the microbiome was carried out (Figure 4.4C). 
Interestingly, we found many taxa, already known to be altered in IBD patients, to be 
modified also during DSS treatment. For instance, at the phylum level, Actinobacteria and 
Firmicutes were reduced upon inflammation in favour of an enrichment of Bacteroidetes 
(Figure 4.4C-D) [118]. At the family level instead, we observed a significant reduction of 
Lachnospiraceae and Christensenellaceae (Figure 4.4D) [120], while the genus 
Desulfovibrio was strongly enriched in DSS-treated mice (Figure 4.4D), similarly to what 
reported in patients [158]. 
This alteration of the healthy microbial composition, referred to as dysbiosis, is 
characterizing DSS-treated mice as well as IBD patients [120], [159].  
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Figure 4.4 DSS treated mice experience gut microbiota dysbiosis (A) Microbiome clustering based on 
unweighted Principal Coordinate Analysis (PCoA) UniFrac metrics of faecal gut microbiota derived 
from DSS treated (blue dots) and untreated (red dots) mice. (B) Rarefaction curves showing microbial 
microbial richness and evenness on the Shannon index (left panel) and richness based on the Chao1 
index (right panel). (C) Bar plots of the taxonomic composition showing relative abundances >1% of 
bacterial phyla (left panel) and families (right panel). (D) P value of the comparison between the 
relative abundances of different taxa between DSS treated and untreated mice. Blue bars, taxa 
enriched in DSS treated mice, red bars, taxa enriched in untreated controls. Statistical significance 
was calculated with One Way Anova test with LSD post-hoc test. 
 
4.2 Antibiotic-induced dysbiosis 
 
To alter the gut microbiota composition by mean of antibiotics administration, CXCR6 
EGFP/+ mice were treated for two weeks with a broad- spectrum antibiotic cocktail (ABX, 
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vancomycin, metronidazole, ampicillin, neomycin), targeting both aerobic and anaerobic 
bacteria. Subsequently, mice were either maintained in ABX treatment (ABX, left scheme) 
or reconstituted by oral gavage with mucosa-associated and faecal bacteria (FMT; Figure 
4.5A, middle scheme). The complete depletion of bacteria was confirmed by qPCR analyses 
and CFU plating. 
To evaluate whether the characteristics of the microbiota utilized to reconstitute the 
gastrointestinal tract upon ABX treatment might impact, mucus and feces derived from 
healthy mice (nFMT, normobiotic Faecal Microbiota Transplantation) or from mice with 
intestinal dysbiosis (dFMT, dysbiotic FMT) were engrafted to ABX-treated mice. Dysbiotic 
microbiota was obtained from mice with acute DSS-induced colitis. To address the 
presence of inflammation these groups were compared to DSS-treated mice as positive 
control (Figure 4.5A, right scheme).  
The histological evaluation of colonic tissues revealed that neither antibiotic treatment nor 
recolonization with normobiotic or dysbiotic microbiota induced macroscopic changes in 
the colonic tissue architecture (Figure 4.5B). Next, we performed qPCR analyses on tissue 
derived mRNA to address the expression of il-6, il-17A, tnf, mcp-1 and il-12. We observed 
that all the above-mentioned microbiota-manipulating treatments failed to upregulate 
inflammatory genes (Figure 4.5D).  
Thus, we can conclude that microbiota depletion through short-term oral antibiotics 
treatment or its reconstitution with either normobiotic or dysbiotic microbiota do not 
induce a macroscopic gut inflammation. 
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Figure 4.5 Antibiotic treatment does not alter mucosal architecture under homeostatic conditions. (A) 
Schematic representation of the treatments. (B) H&E staining and cumulative histological score on 
colon specimens of untreated (open circles), antibiotic treated (ABX, closed circles), transplanted with 
eubiotic (open squares) or dysbiotic FMT (closed squares) and of DSS-treated mice (closed diamonds). 
Scalebar 100um. (C) Colonic expression levels of Il6, il17a, tnf, mcp-1, il-12 in untreated (white bars), 
ABX-treated (gray bars), reconstituted with eubiotic (striped bars) or dysbiotic (dotted bars) FMT or 
in DSS-treated mice (black bars). Statistical significance was calculated with Kruskal wallis test with 
Dunn’s multiple comparison correction. P < 0.05 (*), P < 0.01 (**) were regarded as statistically 
significant. Outliers were detected with Grubb’s test. 
 
Though no macroscopic signs of inflammation were present in mice treated with 
antibiotics, we wondered if a modulation of the immune response at the cellular level 
might have occurred. We performed flow cytometric analyses on freshly isolated colonic 
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LPMCs of mice treated with a cocktail of whole-spectrum antibiotics or reconstituted with 
normobiotic or dysbiotic microbiota, as described above. The microbiota depletion was 
sufficient to induce a significant expansion of iNKT cells in the colon of adult mice, both in 
terms of frequency and absolute numbers (Figure 4.6A-C, upper panels). Importantly, 
reconstitution of the gut microbiota with a normobiotic FMT restored iNKT cell frequency, 
a phenomenon that was not observed upon microbial reconstitution with the microbiota 
derived from DSS- treated mice (Figure 4.6B). Conversely, CD4+ T cells accumulation in the 
colon was unaffected by antibiotic treatment or by microbiota recolonization, regardless 
its origin (Figure 4.6A-C, lower panels). 
 
Figure 4.6 Antibiotic treatment influences colonic iNKT cell frequency (A) Representative dot plots, (B) 
cumulative frequency and (C) absolute numbers of iNKT cells (upper panels) and CD4+ T cells (lower 
panels) in untreated mice (open circles), ABX-treated mice (closed circles), mice reconstituted with 
normobiotic FMT (open squares) or with microbiota from DSS-treated mice (dysbiotic FMT, closed 
squares). Statistical significance was calculated with Kruskal wallis test with Dunn’s multiple 
comparison correction. P < 0.05 (*) were regarded as statistically significant. Outliers were detected 
with Grubb’s test. 
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To further characterize the mucosal T cell population upon microbiota manipulation, we 
analyzed the expression of specific activation markers and intracellular cytokines. We 
found that CD69, a surface molecule associated to T cells functional activation, in both iNKT 
and CD4+ T cells isolated from ABX-treated mice did not significantly differ from that of cells 
isolated from mice reconstituted with a normobiotic microbiota (Figure 4.7A). Conversely, 
re-colonization of ABX-treated mice with a dysbiotic microbiota triggered an upregulation 
of CD69 expression by iNKT cells. Despite no great difference in terms of cytokine profile 
was found upon ABX treatment and reconstitution with a normobiotic microbiota, IFNγ 
secretion was enhanced upon dysbiotic FMT in both iNKT cells and CD4+ colonic T cells 
(Figure 4.7B). 
Collectively, these results suggest that expansion of colonic iNKT cells and CD4+ T cells is 
differentially modulated upon the manipulation of the intestinal microbiota in the absence 
of intestinal inflammation. Moreover, the microbiota composition influences both the 
accumulation and the functional activation of colonic iNKT cells and CD4+ T. 
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Figure 4.7 Antibiotic treatment influences colonic iNKT cell frequency (A) Absolute numbers of CD69+ 
cells among iNKT cells (upper panels) and CD4+ T cells (lower panels) in untreated mice (white bars), 
ABX-treated mice (light gray bars), mice reconstituted with normobiotic FMT (dark gray bars) or with 
microbiota from DSS-treated mice (dysbiotic FMT, black bars) (B) Cytokine production by iNKT cells 
(upper panel) and CD4+ T cells (lower panel) in untreated, ABX-treated, reconstituted with 
normobiotic or with dysbiotic FMT. Statistical significance was calculated with Kruskal Wallis test with 
Dunn’s multiple comparison correction. P < 0.05 (*) were regarded as statistically significant. Outliers 
were detected with Grubb’s test. 
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4.3 Therapeutic modulation of gut microbiota during intestinal 
inflammation 
 
Our previous results demonstrate that the mucosal immune response, and especially T 
cells, become fully activated in the presence of a dysbiotic microflora associated to 
intestinal inflammation and that, even in the absence of inflammation, specific subsets of 
T cells can be functionally affected by the alteration of the gut microbiota composition. 
Starting from these observations, we asked whether gut microbiota manipulation through 
faecal microbiota transplantation (FMT) could impact on T cells functions and whether this 
could have a therapeutic relevance for the treatment of intestinal inflammation. 
 
4.3.1 FMT ameliorates DSS-induced acute colitis 
To evaluate the functional effects of therapeutic FMT, mucus and faeces derived from 
normobiotic untreated donor mice were collected and transplanted by oral gavage to DSS-
treated colitic recipient mice for 3 consecutive days, according to the scheme described in 
Figure 4.8A. When sacrificed in the acute phase of DSS-induced inflammation, FMT-treated 
mice showed reduced signs of intestinal inflammation, as indicated by a reduction in weight 
loss (Figure 4.8B) and increased colon length (Figure 4.8C). These effects were associated 
to an increase in variability in the histological score of mice treated with FMT compared to 
the ones treated with DSS only (Figure 4.8D). Some mice experienced a global amelioration 
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of the intestinal inflammation, measurable with all the histological parameters used to 
score the tissue (Figure 4.8E).  
 
Figure 4.8 Therapeutic FMT ameliorates DSS-induced experimental colitis (A) Schematic representation 
of FMT treatment during acute DSS experimental colitis. (B) Weight loss and colon length (C) of 
untreated (striped boxes), colitic (black boxes), or colitic mice treated with FMT (white boxes). (D) 
H&E staining (scalebar 100µm) and cumulative histological score of colon specimens obtained from 
DSS-treated and FMT-treated mice; (E) Detailed histological evaluation of mice with decreased 
histological score (white boxes, n=5) compared to DSS-treated mice (black boxes, n=5). Statistical 
significance was calculated with Mann-Whitney test for comparison between two groups and Kruskal 
wallis test with Dunn’s post-test for multiple comparison. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) 
were regarded as statistically significant. Outliers were detected with Grubb’s test. 
 
Since DSS-induced colitis is a self-resolving disease experimental model [155], to address if 
FMT beneficial effects were limited to a specific timeframe, we sacrificed mice also at a 
later timepoint. Colon length measurement fifteen days after the start of the treatment 
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indicated that the acute inflammation was resolved in the DSS-treated group (Figure 4.9A). 
Nonetheless, histological evaluation demonstrated that the intestinal tissue of DSS-treated 
mice remained injured also at later timepoints. Conversely, FMT treatment of colitic mice 
resulted in mucosal protection in half of the mice sacrificed at day 15 (Figure 4.9B).  
These results suggest that FMT might sustain cellular processes involved in the resolution 
of the intestinal inflammation in DSS-treated mice. 
 
Figure 4.9 FMT contributes to accelerate the resolution of intestinal inflammation. (A) Colon length and 
(B) histological evaluation of DSS treated (black dots) and DSS + FMT treated (open dots) of mice 
sacrificed 11 or 15 days after the beginning of the treatment. Statistical significance was calculated 
with Mann-Whitney test. P < 0.05 (*), P < 0.01 (** were regarded as statistically significant. Outliers 
were detected with Grubb’s test. 
 
In agreement with previously published reports [144], FMT reduced the expression of the 
pro-inflammatory il1β (Figure 4.10A) in the colonic mucosa. To evaluate whether FMT 
might exert protective effects on gut barrier functions, the colonic expression of 
antimicrobial peptides and mucins was also tested (Figure 4.10C). The colonic expression 
of Camp and s100A8, two antimicrobial peptides playing anti-inflammatory roles during 
acute intestinal inflammation [160] were upregulated upon FMT administration. Similarly, 
a tendency toward up-regulation of Muc1 and Muc4, two mucins exerting anti-
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inflammatory functions in response to pathogens [102], and a downregulation of Muc3 
were observed by FMT treatment in acute DSS-colitis. 
 
Figure 4.10 FMT modulates the colonic expression of pro-inflammatory genes, anti-microbial peptides 
and mucins. (A) Colonic expression levels of il1β in colitic (black boxes) and FMT-treated (white bars) 
mice. (B) Colonic expression levels of camp, S100A8 (C) and muc1, muc3, muc4 in untreated (white 
boxes), DSS treated (black boxes) or DSS + FMT treated (gray boxes) mice. Statistical significance was 
calculated with Mann-Whitney test for comparison between two groups and Kruskal wallis test with 
Dunn’s post-test for multiple comparison. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) were regarded 
as statistically significant. Outliers were detected with Grubb’s test. 
 
4.3.2 FMT treatment induces variations in gut microbiota composition and 
metabolic activity in colitic mice 
Having observed that mice experiencing DSS-induced acute colitis are characterized by a 
state of microbial dysbiosis, we hypothesized that FMT beneficial effect could correlate 
with a restoration of a healthy microbiota composition. Thus, we evaluated variations in 
the microbial communities in colitic mice treated or not with FMT.  Faecal samples of DSS 
and DSS + FMT mice were collected at day 11 post colitis induction and subjected to 
microbiome profiling using 16S rRNA gene sequencing on the Illumina MiSeq platform. An 
unweighted UniFrac-based comparison of the microbiota isolated from untreated, DSS and 
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DSS + FMT-treated recipient mice was performed. As shown in Figure 4.11A, principle 
component analysis (PCoA) differentiated untreated mice from the experimental groups 
(DSS and DSS + FMT). The intestinal microbiota of DSS-treated mice receiving or not a FMT 
did not macroscopically differ at sacrifice, possibly due to similar relative abundances of 
the top 10 most abundant species among DSS and DSS + FMT-derived samples (Figure 
4.11C). Similarly, the microbiota isolated from DSS + FMT treated mice did not show an 
increase in α-diversity when compared to colitic mice derived microbiota, as reflected by 
the Chao1 and Shannon indexes (Figure 4.11B). 
Nonetheless, a detailed phylogenetic analysis of the taxonomic composition of the 
microbiome of colitic mice treated or not with FMT showed that the reduced inflammatory 
conditions observed upon FMT administration were associated to variations in the 
abundance of specific taxa, including an increase in Firmicutes and a reduction of 
Verrucomicrobia (Figure 4.11D). Significant changes towards restoration of normobiosis 
were detected among the less abundant families belonging to the Firmicutes phylum in the 
DSS + FMT–derived microbiota. For instance, Clostridiaceae, which were expanded in colitic 
mice, were reduced upon FMT and returned to levels comparable to those observed in 
untreated mice (Figure 4.11E).  On the other hand, FMT-derived samples showed 
significant increases of beneficial commensals, also used in probiotics preparations [161], 
including Lactobacillaceae and Streptococcus sp., and of the SCFA-producing taxa 
Erysipelotrichaceae, Odoribacter and Olsenella (Figure 4.11E-F), taxa usually reduced in IBD 
patients [118]–[120].  
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Figure 4.11 Gut microbiota analysis upon FMT treatment in colitic mice (A) Microbiome clustering 
based on unweighted Principal Coordinate Analysis (PCoA) UniFrac metrics of faecal gut microbiota 
derived from DSS treated (blue dots), DSS+FMT treated (orange dots) and untreated (red dots) mice. 
(B) Rarefaction curves microbial richness and evenness on the Shannon index (left panel) and showing 
microbial richness based on the Chao1 index (right panel) (C) Relative abundance of the top 10 most 
abundant OTUs in DSS (blue) and DSS + FMT (red) treated mice. (D) Bar plots of the taxonomic 
composition showing relative abundances >1% of bacterial phyla (d, left panel) and families (d, right 
panel). (E) Pie charts showing the relative abundance of the less abundant families belonging to the 
Firmicutes phylum. (F) P value of the comparison of the relative abundances of different taxa between 
DSS (blue) and DSS + FMT (red) treated mice. Statistical significance was assessed through One way 
ANOVA with LSD post-hoc test * p<0.05  
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In addition to an alteration of the gut microbiota composition, IBD patients have been 
reported to be characterized also by a perturbation in bacterial metabolites [162]. To 
unravel if this was the case also in DSS- and DSS + FMT- treated mice, we studied faecal 
bacterial metabolites with a metabolomic approach. As already observed in human IBD 
patients [162], DSS-treated mice showed increased faecal content of complex sugars 
including lactose and maltose, a possible consequence of defective intestinal absorption, 
which were normalized upon FMT-treatment. Similarly, glutamic acid, a metabolite altered 
in IBD patients [163], decreased upon FMT while gluconic acid and dihydroxiacetone, 
involved in natural detoxification activities [164],  increased upon FMT (Figure 4.12). 
Altogether, these findings suggest that therapeutic FMT exert beneficial effects during 
acute intestinal inflammation and that this may arise from the reshuffling of the microbiota 
communities towards restoration of functional normobiosis.   
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Figure 4.12 FMT modulates gut microbiota metabolism (A) Partial Least square-discrimination analysis 
(PLSD-DA) and heat map of metabolites that have contributed most to class separation and (B) 
volcano plot on metabolomics data of faecal samples of untreated, DSS and DSS + FMT treated mice. 
 
4.3.3 The transplant of dysbiotic microbiota does not ameliorate intestinal 
inflammation 
Our previous data indicated that the composition of the microbiota transplanted was 
essential to modulate the mucosal immune response under steady state conditions (Figure 
4.6). Thus, we obtained donor mucus and faecal samples from normobiotic or dysbiotic 
mice, i.e from healthy mice left untreated or treated for 7 days with DSS, and we performed 
FMT in colitic mice as described in Figure 4.8. As expected, an amelioration of the intestinal 
inflammation was reported in mice receiving a normobiotic FMT but not in those receiving 
a dysbiotic FMT, as demonstrated by an increase in colon length (Figure 4.13A) and a 
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decrease, albeit not significant, in the expression levels of colonic pro-inflammatory il1b 
and tnf (Figure 4.13B). 
Consistently, the microbial composition of recipient mice that were transplanted with a 
dysbiotic FMT was also more similar to that of DSS-treated mice, enriched in pathobionts 
such as E.Coli/Shigella (Figure 4.13C) while the microbiota of mice receiving a normobiotic 
FMT were more similar to that of untreated mice, enriched in protective SCFA-producing 
bacteria (Figure 4.13D). Consistently, metabolomic analysis of the faeces of recipient mice 
treated with normobiotic FMT revealed the upregulation of metabolic pathways associated 
with the resolution of the inflammation (Figure 4.13E), i.e. metabolites associated to 
scavenging of free radicals (d-glucunolactone) and metals (gluconic acid) [163], to the 
control of ROS production and neutrophils activity (hydroxiphenillactic acid) and 
chemotaxis (LPA) [164] , and to SCFA production (Valeric acid) [81].  
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Figure 4.13 Transplant of normobiotic or dysbiotic microbiota. (A) Colon length of DSS (black boxes), 
DSS + nFMT (white boxes) or DSS + dFMT (gray boxes) treated mice. (B) Colonic expression of tnf and 
il1b in DSS (black boxes), DSS + nFMT (white boxes) or DSS + dFMT (gray boxes) treated mice. (C) 
Relative abundance of E.Coli/Shigella and (D) Olsenella in untreated (dotted white boxes), DSS treated 
(black boxes), DSS + nFMT (white boxes) and DSS + dFMT (gray boxes) mice.(E) Partial Least square-
discrimination analysis (PLSD-DA) on metabolomics data (right panel), heat map and cluster plot of 
metabolites that have contributed most to class separation (left panel) of faecal samples of DSS, DSS 
+ nFMT and DSS + dFMT treated mice. Statistical significance was calculated with Kruskal wallis test 
with Dunn’s post-test for multiple comparison. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) were 
regarded as statistically significant. Outliers were detected with Grubb’s test. 
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Relevant differences between the two types of donors used for FMT experiments were 
confirmed by metagenomic analyses on the transplanted faecal material (Figure 4.13). As 
previously shown in Figure 4.4, also in this experimental setting the microbiota of dysbiotic 
mice was characterized by a contraction of Bacteroidales S24-7, Lachnospiraceae and 
Bifidobacteriaceae and an expansion of Enterobacteriaceae and Bacteriaceae as compared 
to that of normobiotic mice (Figure 4.14A). The dysbiotic microbiota transplanted 
displayed also a lower microbial richness and evenness, as indicated by the Shannon and 
Chao1 α-diversity measurement (Figure 4.14B).  
 
 
 
Figure 4.14 Differences between normobiotic and dysbiotic microbiota donors. (A) Comparison of 
relative abundancies of different taxa between normobiotic (outer chart) and dysbiotic (inner chart) 
faecal microbiota. (B) Rarefaction curves showing microbial richness based on the Chao1 index (right 
panel) and microbial richness and evenness on the Shannon index (left panel). 
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Collectively, these results suggest that the normobiotic nature of the donor microbiota is a 
key prerequisite for the restoration of a healthy microbial composition and the resolution 
of the inflammation in the recipient. 
4.3.4 The beneficial effect of FMT is independent on the housing origin of the 
donor mice 
Next, we evaluated if normobiotic donors of different origins might be equally capable to 
control intestinal inflammation when transplanted into colitic mice. Mucus and faecal 
samples were isolated from age and sex matched C57Bl/6 mice obtained from different 
sources, i.e. from two commercial animal vendors (Charles River srl and Envigo srl) and 
from in-house bred C57Bl/6 colony (IEO animal facility). Interestingly, the FMT performed 
with the microbiota isolated from the different normobiotic donors was equally capable to 
control intestinal inflammation, as shown by similar colon length (Figure 4.15A), 
histological score (Figure 4.15B), and expression of colonic pro-inflammatory genes such 
as tnf and il1b (Figure 4.15C). 
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Figure 4.15 Transplant of microbiota from donors of different housing origins. (A) Colon length and (B) 
cumulative histological score of DSS (black boxes), DSS + IEO-FMT (white boxes), DSS + CR-FMT 
(dotted boxes) and DSS + Envigo-FMT (striped boxes) treated mice. (C) Colonic expression of tnf and 
il1b in DSS (black boxes), DSS + IEO-FMT (white boxes), DSS + CR-FMT (dotted boxes) and DSS + 
Envigo-FMT (striped boxes) treated mice. Statistical significance was calculated with Kruskal Wallis 
test with Dunn’s post-test for multiple comparison. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) were 
regarded as statistically significant. Outliers were detected with Grubb’s test. 
 
4.3.5 FMT beneficial effect in intestinal inflammation relies on the transplant of 
normobiotic microbial ecologies 
As previously observed [58], [165], [166], donor mice sharing the same genetic background, 
sex and age, but raised in different animal facilities harbored a genetically similar, though 
not identical, microbiota (Figure 4.16A) capable to perform overlapping metabolic 
activities when transplanted into a colitic recipient mouse (Figure 4.16B).  
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Figure 4.16 Differences between microbiota donors of different housing origins. (A) Comparison of 
relative abundancies of different taxa between Envigo- (outer chart), Charles River- (CR) (middle 
chart) or IEO-derived faecal microbiota. (B) PCA showing the partial least square-discrimination 
analysis (PLSD-DA) on metabolomics data between Envigo-, Charles River- (CR) or IEO-derived faecal 
microbiota.  
 
In accordance to very recent data [86], 90 to 93% of the total taxa relative abundance of 
untreated normobiotic mice donors of different housing origins, was composed by a similar 
core microbial ecology of Bacteroidales S24-7 (30-45% among groups), Lachnospiraceae 
(28-38%), Lactobacillaceae (6-15%), Ruminococcaceae (5-8%), Rikenellaceae (3-6%), 
Bifidobacteriaceae (1-2%) and Erysipelotricaceae (1-5%), that in dysbiotic mice accounted 
only for a total 75% (Figure 4.17). These taxa have been functionally associated to 
homeostatic metabolic activities, including SCFA production leading to Treg cells 
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differentiation and IL-10-production [82], [83]. On the contrary, the taxa expanded in 
dysbiotic mice accounting for a 25% of the total microbial ecology, which were either 
completely absent or present in extremely low abundancies in normobiotic mice, were 
mostly Enterobacteriaceae, Bactaeriaceae, Rhodospirillaceae, Streptococcaceae, (Figure 
4.17) i.e. taxa that have been shown to be increased both in colitic mice and IBD patients 
[118], [167]. 
 
Figure 4.17 Variations of microbial ecologies among microbiota donors. Comparison of relative 
abundancies of different family between normobiotic-, IEO-, CR- Envigo- and dysbiotic-derived faecal 
microbiota.  
 
Taken together, these data indicate that only a normobiotic healthy microbiota, composed 
by bacteria that are contributing to beneficial ecological functions, can ameliorate the 
intestinal inflammation.  
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4.4 Modulation of the colonic immune response by therapeutic 
FMT  
 
Since the host immune system and the gut microbiota shape each other throughout life 
[71], we next asked if the gut microbiota reshuffle induced by therapeutic FMT 
administration in colitic mice could trigger variations in the frequencies and in the 
functional activities of the immune cell colonic infiltrate. 
 
4.4.1 Therapeutic FMT influences T cell abundance and proliferation 
The presence of specific bacterial strains in the gut has been linked to the differentiation 
and expansion of conventional [58] and unconventional [93] T lymphocytes. An increase of 
iNKT cell frequency, but not absolute numbers, was observed in DSS + FMT- treated mice 
after FMT, while CD4+ T cells were decreased both in frequency and numbers (Figure 4.18 
A). This observation might find an explanation in their reduced proliferative capacity (Figure 
4.18B).  Given that iNKT cells isolated from FMT-treated and untreated mice exhibited 
similar Ki67 expression (Figure 4.18B), the increase of iNKT cell percentage on total CD3+ 
lymphocytes was likely a consequence of the overall reduction of CD4+ T cells rather than 
of their expansion. 
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Figure 4.18 Modulation of T cell populations upon FMT. (A) Representative dot plots (upper panels), 
frequencies and absolute numbers (lower panels) of colonic CD4+ T cells and iNKT cells in DSS-treated 
(black bars) and FMT-treated (white bars) mice 11 days after starting DSS administration (B) 
Representative dot plots, (upper panels), frequencies and absolute numbers (lower panels) of Ki67-
expressing colonic CD4+ T cells and iNKT cells in DSS-treated (black bars) and FMT-treated (white 
bars) mice. Statistical significance was calculated with Mann-Whitney test. P < 0.05 (*), P < 0.01 (** 
were regarded as statistically significant. Outliers were detected with Grubb’s test. 
 
4.4.2 Therapeutic FMT influences the myeloid cell compartment and its antigen 
presentation potential 
Antigen presenting cells (APC) and immune cells of myeloid origin infiltrating the inflamed 
lamina propria have been shown to contribute to sustain and propagate intestinal 
inflammation in IBD patients [95] and in DSS-induced acute colitis model [156].  Thus, we 
analysed by flow cytometry the myeloid cell compartment (Figure 4.19). Following 
therapeutic FMT, a reduction in F4/80+ macrophages and CD11b+Ly6G+ neutrophils 
frequency (Figure 4.19A) and partially in absolute numbers (Figure 4.19B) was observed. 
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In contrast, CD19+B cells and CD11c+dendritic cell abundances were mostly unaffected 
(Figure 4.19A-B).  
Moreover, several evidences suggest that mucosal T-helper cells activation during 
intestinal inflammation depends on antigenic stimulation [95]. Upon FMT treatment, both 
the number of colonic MHC-II-expressing professional APC, including dendritic cells and 
macrophages (Figure 4.19C), and MHC-II expression levels on APC (Figure 4.19D) were 
strongly reduced.  
These observations lead us to hypothesise that FMT might directly act on the antigen 
presenting capacity of professional APC. 
 
Figure 4.19 Modulation of antigen presenting cells upon FMT. (A) Representative dot plots and 
frequency of dendritic cells (CD45.2+CD3-CD11c+), macrophages (CD45.2+CD3-F4/80+CD11b-), B cells 
(CD45.2+CD3-CD19+), neutrophils (CD45.2+CD3-Ly6g+CD11b+) in DSS-treated (left panels) and FMT-
treated (right panels) mice 11 days after starting DSS administration. (B) Frequency and absolute 
numbers of colonic dendritic cells, macrophages, B cells, neutrophils in DSS-treated (black boxes) and 
DSS+FMT-treated (white boxes). (C) Absolute numbers of MHC-II expressing colonic dendritic cells, 
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macrophages, B cells and neutrophils in DSS (white boxes) and DSS+FMT treated (black boxes) mice. 
(D) Representative histograms of MHC-II expression and cumulative Mean fluorescence intensity 
(MFI) on colonic dendritic cells, macrophages, B cells, neutrophils in DSS (black boxes) and DSS+FMT 
(white boxes) treated mice. Statistical significance was calculated with Mann-Whitney test. P < 0.05 
(*), P < 0.01 (**) were regarded as statistically significant. Outliers were detected with Grubb’s test. 
 
Collectively, these data indicate that therapeutic FMT exerts a specific effect on intestinal 
infiltrating immune cell population frequency and phenotype. 
 
4.5 Bacterial antigen presentation on T cell activation during FMT 
treatment 
 
We next evaluated if FMT administration might influence specific immune cells functional 
activities directly correlated to bacterial antigens presentation. 
The faeces of untreated, DSS-treated and FMT-treated mice were collected and used to 
stimulate in-vitro intestinal lamina propria mononuclear cells (LPMC) freshly isolated from 
healthy mice. The infection was stopped after 2 hours of stimulation by adding Gentamycin, 
Penicillin and Streptomycin antibiotics. The cells were left in culture for 96 hours and their 
phenotype was assessed by flow cytometry (Figure 4.20). 
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Figure 4.20 In-vitro bacterial antigen presentation assay (A) Schematic representation of in vitro 
stimulation of mononuclear cells with faeces derived from untreated, DSS treated and DSS + FMT 
treated mice 
 
This in vitro assay perfectly recapitulated what observed in vivo. MHC-II levels on dendritic 
cells, macrophages and monocytes were down-regulated upon exposure in vitro to normal 
(untreated) or FMT-derived microbiota, as compared to the ones exposed to DSS-derived 
faeces (Figure 4.21A). 
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Figure 4.21 The antigen presentation assay recapitulates in vivo FMT effect (A) Mean fluorescence 
intensity (MFI) of MHC-II on dendritic cells, macrophages, monocytes, neutrophils exposed in vitro to 
faeces isolated from untreated (white bars), DSS (black bars) and DSS + FMT (grey bars) treated mice. 
(B) IFNγ, TNF and IL1b cytokines levels in supernatants of LPMC in vitro exposed to faeces isolated 
from untreated (white bars), DSS (black bars) and DSS +F MT (grey bars) treated mice. Cytokines levels 
were measured with Cytokine Bead Array (BD) and normalised to unstimulated spontaneous 
secretion by LPMC. Statistical significance was calculated with Kruskal wallis test with Dunn’s post-
test for multiple comparison. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) were regarded as statistically 
significant. Outliers were detected with Grubb’s test. 
 
Cytokines produced by mucosal immune cells play a pivotal role in the initiation and 
propagation of intestinal inflammation, as in the maintenance of homeostasis [96]. To 
evaluate the cytokine milieu generated upon exposure to FMT-derived microbiota, we 
analysed the supernatants of stimulated intestinal LPMC. Interestingly, LPMC exposed to 
FMT-derived microbiota showed low levels of pro-inflammatory cytokines, such as TNF, 
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IL1β and IFNγ, which were instead increased in the supernatants of LPMC exposed to DSS-
derived microbiota (Figure 4.21B).  
Moreover, CD4+ T cell expansion occurred only after stimulation with DSS-derived, but not 
with untreated- or FMT- derived microbiota (Figure 4.21C). Likewise, DSS-derived 
microbiota also induced a strong upregulation of the CD69 activation marker on intestinal 
CD4+ T cells, while untreated or FMT-derived microbiota failed to do so (Figure 4.22A).  
Interestingly, when an MHCII blocking antibody was added to the medium, the expression 
of CD69 on T cells was not affected, suggesting that in this in vitro setting upregulation of 
CD69 was not antigen dependent (Figure 4.22A). Conversely, T cell cytokine production 
seemed to be mainly dependent on antigen presentation, as both IFNγ and IL-10 secretion 
were significantly reduced in presence of MHC-II blockade (Figure 4.22B-C). More 
importantly, only FMT-derived microbiota increased IL-10 secretion by CD4+ T cells (Figure 
4.22B-C). 
Altogether these data confirm a crucial role for bacterial antigen presentation in the 
tolerogenic skewing of innate and adaptive colonic immune populations upon FMT 
treatment. 
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Figure 4.22 MHC-II-dependent presentation of FMT- derived bacterial antigens is required for CD4+ T 
cells cytokine profile skewing. (A) CD69 expression on intestinal CD4+ T cells exposed in vitro to faeces 
isolated from untreated (white boxes), DSS (black boxes) and DSS + FMT (grey boxes) treated mice in 
the presence (striped bars) or absence (filled bars) of blocking MHC-II antibodies. (B) Frequencies 
and representative dot plots of IFNγ and IL-10 secreting intestinal CD4+ T cells exposed in vitro to 
faeces isolated from untreated (white bars), DSS (black bars) and DSS + FMT (grey bars) treated mice 
in the presence (striped bars) or absence (filled bars) of blocking anti-MHCII antibodies. Statistical 
significance was calculated with Mann-Whitney test for comparison between two groups and Kruskal 
Wallis test with Dunn’s post-test for multiple comparison. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) 
were regarded as statistically significant. Outliers were detected with Grubb’s test.  
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4.6 The role of FMT-driven IL-10 secretion  
 
The production of the tolerogenic IL-10 is one of the key mechanisms for the maintenance 
of mucosal homeostasis and for the regulation and resolution of intestinal inflammation 
[39], [40]. Our in vitro experiments indicated that IL-10 production by intestinal immune 
cells might be critically involved in the tolerogenic mechanisms triggered by therapeutic 
FMT during experimental colitis (Figure 4.22B). We thus wondered if IL-10 production 
might be responsible for the observed therapeutic effects of FMT in vivo. 
 
4.6.1 Colonic IL-10 production is increased upon FMT treatment 
Colonic tissue lysates of DSS + FMT treated mice showed higher amounts of IL-10 protein 
level (Figure 4.23A). With a flow cytometric approach we sought for possible IL-10 
producers among the mucosal immune cell infiltrate and we observed increased 
frequencies of IL-10-producing APC (CD45.2+CD3-Lin+, Figure 4.17B) as well as CD4+ T and 
iNKT cells in the colons of FMT-treated mice as compared to DSS-treated mice (Figure 
4.23C-D).  
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Figure 4.23 IL-10 production increases upon FMT (A) Colonic IL-10 protein level in DSS- (black boxes) 
and DSS + FMT- (white boxes) treated mice. (B) Representative histograms of IL-10 expression and 
cumulative Mean fluorescence intensity (MFI) (left panel) and frequency (right panel) of IL-10-
producing colonic professional antigen presenting cells (CD45+ CD3- MHC-II+) in DSS (black boxes) and 
DSS + FMT (white boxes) treated mice. Summary of cytokines secreted by (C) colonic CD4+ T cells and 
(D) iNKT cells in DSS-treated (black boxes) and FMT-treated (white boxes) mice 11 days after starting 
DSS administration. Statistical significance was calculated with Mann-Whitney test for comparison 
between two groups. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) were regarded as statistically 
significant. Outliers were detected with Grubb’s test.  
 
4.6.2 IL-10 critically contributes to FMT-driven beneficial activity 
To test the specific contribution of IL-10 on the anti-inflammatory properties of FMT, DSS-
treated mice were intraperitoneally injected with IL-10 receptor (IL-10R) blocking antibody 
administered concomitantly to FMT treatment , as shown in Figure 4.24A. Inhibition of the 
tolerogenic functions of IL-10 on IL-10R expressing cells, such as antigen presenting cells 
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(APC), T cells and epithelial cells [168], hampered FMT protective activity as shown by 
reduced colon length (Figure 4.24B),  increased weight loss (Figure 4.24C), and higher 
colonic expression of tnf, ifnγ and il1β (Figure 4.24D). These effects were not observed 
when IL-10R was blocked in colitic mice without a concomitant FMT administration, 
suggesting a direct contribution of microbiota induced IL-10 in mediating FMT-driven 
control of inflammation. 
 
Figure 4.24 In vivo blockade of IL-10 pathway impairs FMT effects. (A) Schematic representation of αIL-
10R blocking antibody administration in colitic mice during FMT treatment. (B) Colon length and (B) 
weight loss of untreated mice (white dotted boxes and open circles) or receiving DSS (black boxes and 
black symbols), or DSS + FMT (white boxes and white symbols) or DSS + αIL-10R (green boxes and 
green symbols), or DSS + FMT + αIL-10R (blue boxes and blue symbols) or mice receiving DSS + FMT 
+ αIL-10R isotype antibody (red boxes and red symbols). (h) Colonic expression of tnf, ifnγ and il1β in 
DSS treated mice (black boxes), DSS + FMT treated (white boxes), DSS + αIL-10R (blue boxes), DSS + 
FMT + αIL-10R treated (green boxes) and DSS + FMT + αIL-10R isotype antibody treated mice (red 
boxes). Statistical significance was calculated with Mann-Whitney test for comparison between two 
groups and Kruskal wallis test with Dunn’s post-test for multiple comparison. P < 0.05 (*), P < 0.01 
(**), P < 0.001 (***) were regarded as statistically significant. Outliers were detected with Grubb’s 
test. 
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As expected, IL-10R blockade reverted the inhibition of CD4+ T cell proliferation occurring 
upon FMT, making it comparable to the levels of DSS- and DSS + aIL10R- treated mice 
(Figure 4.25A). iNKT cell proliferation was not affected by IL-10R blockade (Figure 4.25B).  
Importantly, blocking of IL-10R also resulted in inhibition of IL-10 production by T and iNKT 
cells, possibly through a feedback regulatory loop (Figure 4.25C).  
 
 
Figure 4.25 In vivo blockade of IL-10 pathway impairs FMT effects on T cells (A) Absolute numbers of 
KI67 expressing colonic CD4+ T cells and (B) iNKT cells (right panels) in DSS treated mice (black boxes), 
DSS + FMT treated (white boxes), DSS + αIL-10R (blue boxes), DSS + FMT + αIL-10R treated (grey 
boxes) and DSS + FMT + αIL-10R isotype antibody treated mice (green boxes) and DSS + FMT + αIL-
10R isotype antibody (red boxes). Statistical significance was calculated with Kruskal wallis test with 
Dunn’s post-test for multiple comparison. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) were regarded 
as statistically significant. Outliers were detected with Grubb’s test. 
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4.6.3 Selective elimination of protective bacterial communities impairs FMT-
induced IL-10 production and its beneficial effect 
Further, we addressed the specific contribution of different gut microbiota communities to 
the induction of protective immune-mediated functions exerted by FMT. To do so, as 
shown in Figure 4.26, therapeutic FMT was performed with donor mucus and faeces 
isolated from mice pre-treated for two weeks with different antibiotics, targeting either 
Gram-positive organisms (vancomycin), Gram- negative bacteria (streptomycin), strict 
anaerobes (metronidazole) or having a broad-spectrum bacterial depletion capability (ABX, 
cocktail of vancomycin, metronidazole and streptomycin) [169].  
 
Figure 4.26 FMT of antibiotics treated donors. Schematic representation of the experiment. 
 
The taxonomic composition of the different donor microbiota was analysed by 16S rRNA 
profiling before administration to colitic mice. As expected, the α-diversity of gut 
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microbiota in antibiotics-treated mice was lower as compared to those derived from 
normobiotic samples. The microbiota of mice treated with just one antibiotic displayed an 
intermediate α-diversity (Figure 4.27A). This evidence was also confirmed by plating of the 
faecal material in aerobic and anaerobic conditions (Figure 4.27B). As a proof of concept, 
the microbial population of broad spectrum antibiotic-treated mice was completely 
depleted while, the single use of the three abovementioned antibiotics resulted in a 
selection of the live bacteria thus shaping the overall population (Figure 4.27B). 
The detailed phylogenetic analysis of the taxonomic composition highlighted a relevant 
dysbiosis in the antibiotic- treated donor samples as compared to the untreated 
normobiotic ones (Figure 4.27C). In particular, metronidazole treatment favoured the 
presence of Lactobacillaceae, Bifidobacteriaceae and Erysipelotrichaceae (Figure 4.27D), 
families belonging to the protective normobiotic microbial ecologies [86] previously 
described in Figure 4.17. On the contrary, pathobionts such as, Burkholderiales, 
Listeriaceae and Gastranaerophilales significantly emerged in Vancomycin-treated samples 
at the expenses of the abovementioned protective families (Figure 4.27D). Streptomycin-
treatment, instead, favoured a limited presence of Erysipelotricaceae and 
Ruminococcaceae while not expanding pathobionts (Figure 4.27D), but rather allowing the 
survival of families whose function could be protective or detrimental according to the 
context [118], [170].    
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Figure 4.27 Antibiotics treated microbiota donors. (A) Rarefaction curves showing microbial richness 
based on the Chao1 index (top panel) and microbial richness and evenness on the Shannon index 
(bottom panel) (B) Plating of faecal material derived from untreated, treated with the antibiotic 
cocktail (ABX) or with streptomycin (Strepto), Metronidazole (Metro) or Vancomycin (Vanco) in 
aerobiosis (left) and anaerobiosis (right). (C) Comparison of relative abundancies of different families 
between faecal microbiota obtained from normobiotic (outer chart) and Streptomycin-treated mice 
(inner chart, left panel), or Metronidazole-treated (inner chart, middle panel) or Vancomycin-treated 
mice (inner chart, right panel). (e) Heat map comparing the expression levels of the different taxa 
between faecal microbiota obtained from normobiotic, Streptomycin-, Metronidazole- or 
Vancomycin-treated mice.  
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As expected, among all the experimental groups shown in Figure 4.26 only the FMT 
performed with metronidazole-treated donor microbiota remained fully capable to control 
intestinal inflammation. Indeed, colon length of mice receiving metronidazole treated 
microbiota was higher compared to that of DSS treated mice (Figure 4.28A). Consistently, 
only in this group the colonic expression of the pro-inflammatory il1b was significantly 
decreased (Figure 4.28B).  
 
 
Figure 4.28 Alteration of the healthy microbial ecology by antibiotic treatment selectively abolishes 
FMT beneficial effects. (A) Colon length and (B) il1β colonic expression in DSS-treated (black boxes), 
DSS + Untreated FMT (white boxes), DSS + ABX FMT (red boxes), DSS + Streptomycin FMT (blue boxes), 
DSS + Metronidazole FMT (green boxes) and Vancomycin (Violet boxes)-treated mice). Statistical 
significance was calculated with Kruskal wallis test with Dunn’s post-test for multiple comparison. P 
< 0.05 (*) were regarded as statistically significant. Outliers were detected with Grubb’s test. 
 
The FMT driven inhibition of CD4+ T cell accumulation in the colon lamina propria was 
impaired in mice receiving FMT from antibiotics-treated donors (Figure 4.29A). 
Interestingly, intestinal iNKT cells expansion was triggered upon transplant of microbiota 
from whole-spectrum antibiotics treated donors (Figure 4.29B), in line with our previous 
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results during homeostatic conditions (Figure 4.6) and with published evidences about 
germ free mice [71].  
 
 
Figure 4.29 Alteration of the healthy microbial ecology by antibiotic treatment selectively impairs FMT 
effects on T cells. Absolute numbers of colonic (A) CD4+ T cells and (B) iNKT cells cells isolated from 
DSS-treated (black boxes), DSS + untreated FMT (white boxes), DSS + ABX FMT (red boxes), DSS + 
Streptomycin FMT (blue boxes), DSS + Metronidazole FMT (green boxes) and DSS + Vancomycin FMT 
(Violet boxes)-treated mice. Statistical significance was calculated with Kruskal wallis test with Dunn’s 
post-test for multiple comparison. P < 0.05 (*) were regarded as statistically significant. Outliers were 
detected with Grubb’s test. 
 
IL-10 production by the intestinal immune infiltrate (CD45.2+ cells) remained high in mice 
receiving metronidazole- treated FMT (Figure 4.30), enriched in Lactobacillaceae and 
Bifidobacteriaceae which are known to promote IL-10 production [161]. IL-10 production 
was maintained in dendritic cells and B cells, but also neutrophils and macrophages showed 
higher IL-10 secretion, though not statistically significant, compared to mice treated with 
only DSS or receiving ABX, streptomycin or vancomycin treated FMT (Figure 4.30). 
Conversely, IL-10 production by CD4+ T cells was impaired in all the antibiotic treated 
experimental groups (Figure 4.30).  
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Figure 4.30 Alteration of the healthy microbial ecology by antibiotic treatment selectively impairs FMT 
induced IL-10 production. Frequencies IL-10 secreting colonic total CD45+ immune cell populations or 
gated dendritic cells (CD11c+), neutrophils (Cd11b+ Ly6g+), Macrophages (Cd11b+F4/80+), B cells 
(CD19+) and CD4+ T cells isolated from DSS-treated (black boxes), DSS + untreated FMT (white boxes), 
DSS + ABX FMT (red boxes), DSS + Streptomycin FMT (blue boxes), DSS + Metronidazole FMT (green 
boxes) and DSS + Vancomycin FMT (Violet boxes)-treated mice. Statistical significance was calculated 
with Kruskal Wallis test with Dunn’s post-test for multiple comparison. P < 0.05 (*) were regarded as 
statistically significant. Outliers were detected with Grubb’s test. 
 
These results suggest that FMT anti-inflammatory activity is differentially acting on APC and 
T cells and that the therapeutic effect driven by FMT treatment might be relying primarily 
on IL-10 produced by intestinal B lymphocytes and myeloid derived infiltrating cells.  
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It is well acknowledged that the murine models only partially resemble human pathologies. 
Nevertheless, keeping in mind this caveat, our data clearly show that the manipulation of 
the gut microbiota is associated with a general amelioration of the inflammatory status 
through a modulation of the mucosal immune response. 
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5 Discussion I 
 
The acknowledgement of the association between microbiota dysbiosis and the 
pathogenesis of several immune-related diseases triggered an increasing interest about the 
idea of using microbiota-derived information for diagnostic and therapeutic purposes. The 
clinical complexity of multifactorial diseases, such as IBD, renders the identification of a 
disease-associated dysbiotic profile relatively difficult. Patients diagnosed with the same 
diseases (e.g. Crohn’s disease or Ulcerative colitis) often manifest wide ranges of 
pathological conditions. This high interindividual variability among patients requires an 
individualized approach to undoubtedly link microbiota structure and function and disease 
phenotype [123]. The effort to solve this issue could nonetheless prove effective in the 
detection of early microbial biomarkers of disease. For instance, it has been recently 
reported that a cohort of Parkinson disease patients displayed constipation symptoms and 
dysbiotic shift in gut microbiota composition years before the development of motor 
dysfunction [171], promisingly suggesting the use of microbiota-based screening tests to 
help the early detection of disease development among individuals at risk. The same 
concept has been proposed also for Crohn’s Disease patients. In this context a microbial 
signature associated to the early onset of the pathology was identified after the analyses 
of a large cohort of paediatric treatment-naïve patients [120]. Similarly, the decrease in 
some protective bacterial species in healthy individuals correlated to a higher IBD genetic 
risk score[118]. The diagnostic value of microbial biomarkers could also additionally lie in 
the stratification of patients belonging to similar pathologies, such as UC and CD [121], or 
in the prediction of patient’s responses to defined therapies [172]–[174]. 
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Once suggested a causality link between gut microbiota dysbiosis and the onset of 
intestinal pathologies, it is therefore not surprising that great effort has been posed to offer 
therapeutic approaches aimed at manipulating the gut microbiota status. Among the 
different proposed approaches, antibiotic administration has been taken into 
consideration also in the management of IBD patients, showing positive effects on the 
amelioration of intestinal inflammation in several clinical trials involving CD patients, 
especially in defined pathologic conditions (i.e, postoperative recurrence, perianal fistulae, 
pouchitis [130], [175]. We also showed that metronidazole treatment could contribute to 
the amelioration of colonic inflammation by selecting protective bacteria such as 
Lactobacillaceae, Bifidobacteriaceae and Erysipelotrichaceae (Figure 4.27). However, we 
and others [176] also demonstrated that antibiotics not only modulate gut microbiota 
composition, but also mucosal immune cell activity and frequency (Section 4.2). Their 
administration to patients should therefore take into account antibiotic 
immunostimulatory ability, a condition that in patients with autoimmune disorders could 
easily become a double-edged sword. On top of the abovementioned conflicting 
observations, antibiotic administration to IBD patients has been linked to a worsening of 
their dysbiotic state [120] and to an increased risk in developing Clostridium difficile 
infection, due to a reduction in colonization resistance [70]. As a consequence of these and 
other considerations concerning the long-term administration of antibiotics to IBD 
patients, ECCO guidelines concluded not to recommend their use [177], [178] with the 
notable exceptions, as mentioned before, of postoperative recurrence, perianal fistulae 
and pouchitis in CD patients and before hospitalization for UC patients. 
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On the contrary, other approaches aimed at the manipulation of the gut microbiota quickly 
became increasingly utilised in the clinical practice. For instance, FMT is becoming the first-
line therapy in antibiotic resistant recurrent CDI [131]. However, its therapeutic application 
to other gastrointestinal diseases is at the very beginning and data on its mechanism of 
action during intestinal inflammation are still scarce. While it is known that restoration of 
normobiosis correlates with clinical remission in successful trials involving UC patients 
[141]–[143], it is still unclear whether FMT might have an effect on the immune system. To 
date, results obtained in BALB/c mice suggest that FMT can induce CD4+CD25+ regulatory 
T cells and reduce colonic expression of Il1β and ifnγ [144].  
In our study, we showed that the manipulation of the gut microbiota by FMT induces a 
general amelioration of the inflammatory status in colitic animals (Sections 4.3 ). Moreover, 
analyses of the gut microbiota in our model showed that 3 days of therapeutic FMT are 
sufficient to introduce modifications in the dysbiotic microbiota, with a relevant change in 
the relative proportions of Firmicutes (Figure 4.11). Interestingly, we found an alteration 
of the levels of Erysipelotrichaceae and Lactobacillaceae in DSS-treated mice, similarly to 
what happens in IBD patients [118], [120], and these taxa abundances were restored upon 
therapeutically successful FMT (Figure 4.11). 
It is now acknowledged that the gut microbiota composition is heavily influenced by age, 
gender, genotype, diet and environmental factors [55]. In this context, animal models are 
valuable tools to study complex biological phenomena, such as those occurring during 
intestinal inflammatory processes, while controlling confounding variables. It also emerged 
from several recent studies that different research institutions or commercial vendors 
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might harbour variations in the microbiological environment leading to differences in 
microbiota composition [58], [166]. Here, we showed that the microbiota derived from 
three different sources were equally capable to control intestinal inflammation in our 
experimental model (Figure 4.15), and this ability was dependent on the presence of a core 
microbial ecology composed by Bacteroidales S24-7, Lachnospiraceae, Lactobacillaceae, 
Ruminococcaceae, Rikenellaceae, Bifidobacteriaceae and Erysipelotrichaceae. As recently 
shown also in metabolic diseases [86], this core ecology consists of bacteria from different 
phyla but sharing similar metabolic functions (i.e: SCFA production, pH control, free radicals 
scavenging) and capable to create environmental conditions sufficient to inhibit the growth 
of pathobionts while supporting optimal host health.  We also demonstrated that a healthy 
gut environment, shaped by the presence of a healthy functional microbial ecosystem, is 
also fundamental to instruct the immune system towards homeostasis (Figure 4.13).  
Furthermore, our results provided a strong evidence about the close relationship between 
gut microbiota and the mucosal immune system. We observed that different types of 
microbial dysbiosis, i.e. inflammation-induced and antibiotic-driven, are impacting on T and 
iNKT cell phenotype and functions (Figure 4.3 and Figure 4.6). Moreover, for the first time 
we proved that the gut microbiome modifications upon FMT treatment exert a profound 
impact on both the adaptive and innate mucosal immune system and that this correlates 
with the reduction of the intestinal inflammation (Section 4.4). FMT beneficial anti-
inflammatory effects support changes in immune cell frequencies, reduction of colonic ifnγ 
and il1β, the increase in antimicrobial peptides and mucins, and the decrease of bacterial 
antigen presentation by APC. Most importantly, a normobiotic FMT induces the skewing of 
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innate and adaptive immune cells toward a tolerogenic IL-10 secreting cytokine profile that, 
altogether, concur to restore intestinal homeostasis (Figure 5.1). 
 
 
Figure 5.1 Schematic representation of mucosal immune response regulation by FMT during intestinal 
inflammation. 
 
Among the different tolerogenic mechanisms developed to maintain intestinal immune 
homeostasis [179], we found that IL10 production was one of the most potent anti-
inflammatory pathway induced by FMT administration in colitic mice. Our results are in line 
with the notion that IL-10-deficient mice and patients with genetic defects in the IL-10/IL-
10R pathway develop intestinal inflammation following the onset of a dysbiotic state [180]. 
Several studies report that a probiotic preparation (i.e. #VSL3) composed by a cocktail of 
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eight strains of Lactobacilli and Bifidobacteria is effective in controlling intestinal 
inflammation through the IL-10-mediated restoration of intestinal homeostasis [161]. 
The resolution of intestinal inflammation has been often linked to the functional plasticity 
of CD4+ T cells from pro-inflammatory to tolerogenic IL-10-producing subtypes [53], [181]. 
Upon therapeutic FMT, both CD4+ and iNKT cells produced IL-10 (Figure 4.23). Importantly, 
since IL-10 also negatively affects the proliferative capacity of cells, the overall increased 
availability of colonic IL-10 might be directly responsible for the reduced proliferative 
capacity of T cells (Figure 4.18) together with the decreased antigen presentation potential 
of APC, as shown by their reduced levels of MHC-II (Figure 4.19). This, in turn, might 
contribute to the reduction of the presentation of bacterial antigens to CD4+T cells, known 
to occur in IBD patients [117]. Importantly, colonic HLA-DR expression levels discriminate 
between healthy, quiescent and active IBD patients, confirming a prominent role of MHCII-
dependent antigen presentation in IBD immunopathology [182].  
 
In conclusion, we demonstrated that the restoration of normobiosis could be the first hint 
to simultaneously trigger several immune pathways leading to tolerogenic functions of 
innate and adaptive immune cells that altogether contribute to the resolution of the 
inflammatory processes. These findings represent an important contribution toward the 
elucidation of the complex interplay between the immune system and the gut microbial 
ecosystem and are instrumental for a better understanding of the immune events occurring 
during therapeutic FMT in humans.  
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However, further pivotal aspects concerning FMT mechanisms of action still need to be 
addressed to optimize its translation into the clinics. The relatively low fraction of UC 
patients responding to FMT treatment in the completed RCT (25-30% [141]–[143]), strictly 
associated to an increase in microbiota α-diversity, underlines the presence of a high 
interindividual variability in the response to the treatment. This finding is likely a direct 
consequence of the multifactorial nature of IBD, but it also suggests that an improved 
knowledge about the mechanisms of bacterial engraftment could give useful insights for 
the best selection and clinical management of those patients. Moreover, the transplant of 
multi-donor faecal samples resulted in a higher FMT endoscopic and clinical success by 
reducing the probability to receive ineffective donor stools [143]. Interestingly, this 
observation provides the rationale for more accurate studies of the best donor/recipient 
matching to increase the success rate of FMT. In addition, the combination of FMT with 
other gut microbiota manipulation approaches could increase the engraftment rate by 
favouring the colonization of specific beneficial strains. For instance, as mentioned before 
we showed that metronidazole treatment is selecting protective SCFA-producing and IL10-
inducing bacteria such as Lactobacillaceae, Bifidobacteriaceae and Erysipelotrichaceae 
(Figure 4.27). This, together with other interventions such as diet, could provide a 
favourable environment for the engraftment of the microbiota transplant.  
Intriguingly, induction of a shift in the microbiota composition could have positive effects 
on the host also in other clinical contexts, such as treatment of cancer patients [123]. 
Several studies have shown that the gut microbiome may influence antitumor responses 
by shaping both adaptive and innate immunity and that this relationship could be exploited 
to enhance anticancer therapy efficacy [183], [184]. More recent reports showed a 
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stratification of melanoma patients on the basis of their microbiome. The ones displaying 
high α-diversity and abundance of certain taxa demonstrated a better response to 
checkpoint inhibitor immunotherapy [174], [185].  
These evidences, together with our demonstration of the existence of a close crosstalk 
between the immune responses and the gut microbiota, could thus pave the path to the 
clinical use of a combination of cancer immunotherapy and the gut microbiota 
manipulation. 
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6 Results II 
 
6.1  Characterization of intestinal T lymphocytes in Inflammatory 
Bowel Diseases 
 
Our data indicate that experimental manipulation of the gut microbiota composition during 
intestinal inflammation, as well as in the presence of antibiotic-induced dysbiosis, results 
in an activation of both conventional and non-conventional T cell subsets.  
Since current hypotheses suggest that an abnormal T cell responses against a dysbiotic 
intestinal microbiota in genetically predisposed individuals [153] might be linked to 
Inflammatory Bowel Disease (IBD) pathogenesis, we aimed at evaluating if and which  
phenotypical and functional variations might have occurred in human iNKT and CD4+ T cells 
in a cohort of human IBD patients. 
To phenotypically and functionally characterize T lymphocytes in the intestinal mucosa of 
IBD patients, lamina propria mononuclear cells (LPMCs) were obtained from individuals 
affected by Ulcerative Colitis (UC, n=16), Crohn’s Disease (CD, n=24) or non-inflammatory 
IBD-unrelated intestinal pathologies referred to as healthy donors (HD, n=27) (Figure 6.1). 
Patients were enrolled from March 2014 to July 2018 at the IRCCS Policlinico Ospedale 
Maggiore, Milan, Italy. The clinical characteristics and concomitant therapies of IBD 
patients are summarized in Table  3.6.  
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6.1.1 CD4+ T and iNKT cells infiltrate the lamina propria of IBD patients 
Human iNKT cells were identified by hCD1d:PBS57 Tetramer recognition, whose specificity 
was confirmed by unloaded CD1d tetramer staining (Figure 3.4). 
The whole population of CD3+ tetramerneg conventional T cells did not manifest frequency 
differences between IBD patients and uninflamed donors (Figure 6.1A-B). Similarly, iNKT 
cell frequency was slightly increased in the LPMCs of CD patients compared to UC patients 
and healthy donors, albeit not significantly (Figure 6.1A,C). As already known for other 
tissues [19], also intestinal iNKT cells display a high frequency variability, spanning from the 
0.1% to the 10% of the total CD3+ T lymphocytes (Figure 6.1A-B). iNKT cells were slightly 
more abundant in the intestinal lamina propria than in the peripheral blood (Figure 6.1B), 
in accordance with the notion that most iNKT cells do not circulate but localize 
preferentially within tissues [186]. 
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Figure 6.1 T cells infiltrate IBD patients colon lamina propria. (A) Representative dot plots and (B) 
summary of frequencies of (B) conventional T cells (hCD1d:PBS57 Tetramer-, dotted bars) and of (C) 
colonic iNKT (hCD1d:PBS57 Tetramer+, plain bars) among total CD3+ Lineage- cells in peripheral 
blood (PB) of healthy donors (HD, open triangles, n=15) or IBD patients (IBD, closed triangles, n=5) 
and in the lamina propria (LP) of uniflamed donors (HD, open circles, n=27 ), UC (closed circles, n=16) 
and CD patients (closed squares, n=24). Statistical significance was calculated with Kruskal Wallis test 
with Dunn’s post-test for multiple comparison. P < 0.05 (*) were regarded as statistically significant. 
Outliers were detected with Grubb’s test. 
 
6.1.2 Intestinal iNKT cells express high levels of CD161 and secrete pro-
inflammatory cytokines 
Since T cell surface expression of CD4 and CD161, a tissue-homing integrin highly expressed 
by gut-tropic T cells, have been associated to pathogenic functions in CD patients [109], 
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their expression was also evaluated on intestinal iNKT cells and tetramerneg CD3+ T cells. 
Intestinal iNKT cells were mainly positive for CD4 (Figure 6.2C-D). The double positive CD4+ 
CD161+ population resulted the most abundant, as previously published [187], without 
significant differences among IBD patients and controls (Figure 6.2C-D). Likewise, intestinal 
conventional tetramerneg CD3+ T cells were mainly CD4+ and the majority co-expressed 
CD161 (Figure 6.2A-B), confirming previously published data in CD patients [110] and in UC 
patients [115].  
 
 
Figure 6.2 CD4 and CD161 expression on T cells in colon lamina propria of IBD patients. Representative 
dot plots (right panels) and cumulative frequencies of CD4/CD161 expressing cells among iNKT 
(Tetramer+, D) and conventional T cells (Tetramer-, E) isolated from the LP of HD (left panels), UC 
(middle panels) and CD patients (right panels). Statistical significance was calculated with Kruskal 
Wallis test with Dunn’s post-test for multiple comparison. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) 
were regarded as statistically significant. Outliers were detected with Grubb’s test. 
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To note, colonic or ileal CD localization did not substantially influence neither the frequency 
(Figure 6.3A-B) nor the phenotype (Figure 6.3C-D) of lamina propria iNKT and conventional 
CD3+ T cells. 
 
 
Figure 6.3 Analysis of frequency and phenotype according to colonic or ileal localization. Frequency of 
Tetramer+ (A) or Tetramer-(B) CD3+ LPMC, subdividing HD and CD patients for colonic or ileal disease 
localization.  Frequency of CD161/CD4 expressing Tetramer+ (C) or Tetramer- (D) CD3+ LPMC 
subdividing HD and CD patients for colonic (C) or ileal (I) disease localization. HD colon, n=22; HD 
ileum n=5; CD colon n=13, CD ileum/colon n=11). Statistical significance was calculated with Mann-
Whitney test for comparison between two groups and Kruskal Wallis test with Dunn’s post-test for 
multiple comparison. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) were regarded as statistically 
significant. Outliers were detected with Grubb’s test. 
 
In previous studies the expression of the CD161 marker in conventional T helper cells from 
CD patients identified IL-17-secreting T cell subset (Th17 cells)  [109]. In accordance, we 
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found that CD161 expression correlated with IL-17 secretion both in conventional T and in 
iNKT cells (Figure 6.4A), while CD161neg cells secreted preferentially TNF and IFNγ (Figure 
6.4A). Importantly, both CD161+ and CD161neg iNKT cells secrete moderate levels of IL-13 
when polyclonally re-stimulated ex-vivo (Figure 6.4A), especially those derived from UC 
patients. Interestingly, ex-vivo freshly isolated iNKT cells constitutively secreted relevant 
amounts of cytokines even in the absence of a re-stimulation (Figure 6.4B). They produced 
high amounts of IL-17, IL-13 and TNF, suggesting that the intestinal microenvironment can 
bestow a pro-inflammatory pre-stimulation in vivo. Specifically, CD4+ CD161+ iNKT cells 
derived from CD patients constitutively secreted higher levels of IFNγ and IL-17 compared 
to the one isolated from UC patients and HD. 
 
Figure 6.4 iNKT and conventional T cells are pro-inflammatory in IBD patients. Frequency of pro-
inflammatory cytokines (TNF, IFN, IL17A, IL13) produced (A) upon polyclonal stimulation or (B) 
without stimulation by CD4+CD161+ (upper graphs) or CD4+CD161- (lower graphs) intestinal ex-vivo 
isolated iNKT cells (Tetramer+) or conventional T cells (Tetramer-) from HD (n=27), UC (n=16) and CD 
patients (n=24). Statistical significance was calculated with Kruskal Wallis test with Dunn’s post-test 
for multiple comparison. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) were regarded as statistically 
significant. Outliers were detected with Grubb’s test. 
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Taken together, these data indicate that phenotypically distinct subsets of iNKT cells are 
present in the lamina propria of healthy donors and IBD patients, and that pro-
inflammatory cytokines are secreted by these cells in the intestinal mucosa. 
 
6.2 Generation of human intestinal iNKT cell lines and clones 
 
To characterize iNKT cell role in IBD-associated inflammation through functional in vitro 
assays, iNKT cells were isolated from peripheral blood mononuclear cells, and from healthy 
intestine, ulcerative colitis and Crohn’s disease LPMCs. Upon polyclonal re-stimulation, 5 
stable iNKT cell lines were established. The lines were all positive for PBS57:CD1d tetramer 
staining (Figure 6.5A). The phenotype of these lines reflected in part the expression of CD4 
and CD161 of ex vivo freshly isolated iNKT cells. While CD derived iNKT cell line uniformly 
co-expressed CD4 and CD161, the two different UC-derived lines differentially expressed 
CD161, as observed in vivo (Figure 6.5B).  
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Figure 6.5 Intestinal iNKT cell lines characterization. (A) Dot plots representing the staining with 
CD1d:PBS57 tetramer of iNKT cell lines derived from Peripheral blood, healthy intestine, ulcerative 
colitis (UC) and Crohn’s disease (CD) surgical specimens.(B) Histograms of CD161 expression on iNKT 
cell lines. 
 
Intestinal iNKT cell lines were fully functional when tested in vitro for their response to both 
antigen-specific (Figure 6.6A) and polyclonal stimulation (Figure 6.6B). They resulted in a 
potent secretion of the inflammatory cytokines TNF, IFNγ and IL-13. To note, IL-17 
production by iNKT cells is hardly detectable by ELISA. The addition of CD1d blocking 
antibody to the medium completely blocked the cytokine production induced by antigen 
presentation (Figure 6.6A). 
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Figure 6.6 In vitro activation of intestinal iNKT cell lines. (A) TNF, IFN and IL-13 secretion upon co-
culture of iNKT cell lines with moDC in the absence (white bars) or presence (black bars) of aGalcer 
and of concomitant CD1d blocking (gray bars). (B) Cytokine production by iNKT cell lines upon 
polyclonal (PMA/Ionomycin) stimulation. Statistical significance was calculated with Mann-Whitney 
test for comparison between two groups and Kruskal Wallis test with Dunn’s post-test for multiple 
comparison. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) were regarded as statistically significant. 
Outliers were detected with Grubb’s test. 
 
More than 400 intestinal iNKT cell independent clones were also generated from IBD (UC, 
CD) patients and healthy donors (HD). These clones were characterized by different 
expression levels of TCR expression evaluated as PBS57:CD1d tetramer staining intensity 
(Figure 6.7). To note, obtaining iNKT cell clones from healthy intestinal mucosa was a 
challenging task. Indeed, only a very limited number of stable, but poorly viable, clones 
were obtained after several attempts of cloning.  
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Figure 6.7 Intestinal iNKT cell clone characterization. Low, intermediate and high expression of the 
invariant TCR in iNKT cell clones derived from the intestine of healthy donors (N=12), UC (N=190) or 
CD (N=300) patients. 
 
Similarly to what we observed with iNKT cell lines, antigen-specific ( Figure 6.8A) and 
polyclonal stimulation ( Figure 6.8B) induced a potent secretion of pro-inflammatory 
cytokines also on iNKT cell clones. Interestingly, polyclonally-stimulated UC-derived clones 
showed a more heterogeneous cytokine profile when compared to HD or CD-derived ones 
( Figure 6.8B). To note, IL17 production by iNKT cells is hardly detectable by ELISA.  
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Figure 6.8 In vitro activation of intestinal iNKT cell clones. (A) TNF, IFNγ and IL-13 production by 
representative iNKT cell clones (HD, n=4; CD n=7, UC n=6) upon αGalCer stimulation in the presence 
(gray bars) or absence (black bars bars) of anti hCD1d-blocking antibodies. (B) Cumulative FACS 
analysis of the cytokine profile of 10 HD (out of 12), 50 UC (out of 196) and 50 CD (out of 210) 
intestinal-derived iNKT cell clones upon PMA/Ionomycin stimulation. 
 
6.2.1 Intestinal iNKT cell line and clones from IBD patients are a valuable help to 
study iNKT cell function in IBD 
Finally, to test if intestinal iNKT cells might acquire pathogenic functions against the 
intestinal epithelium upon in vitro activation, iNKT cells were polyclonally stimulated and 
their supernatants, containing pro-inflammatory cytokines (Figure 6.9B), were applied in 
vitro to polarized epithelial Caco2 monolayers (Figure 6.9A). Activated iNKT cells, 
independently from their origin, manifested a pathogenic potential affecting epithelial cell 
monolayer integrity, as demonstrated by decrease of Trans Epithelial Resistance (TEER) 
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(Figure 6.9C). Like conventional Th17 cells [44 and Appendix III] this effect could be 
inhibited upon neutralization of several T cell cytokines, with the notable exclusion of IL-13 
(Figure 6.9D). 
Collectively, these data indicate that the functional phenotype of intestinal iNKT cell lines 
reflects that of ex-vivo isolated intestinal iNKT cells. Hence, these lines and clones can be 
used as an innovative tool to study human intestinal iNKT cells in vitro and assess their 
potential role in gut inflammation. 
 
Figure 6.9 Human iNKT cells are pathogenic against epithelial cells. (A) Schematic representation of 
the experiment. (B) Multiplex analysis of TNF, IFN, IL-17A and IL-13 concentrations in the 
supernatants of polyclonally stimulated iNKT cells. (C) Trans-epithelial resistance (TEER) measured 
upon co-culture of Caco-2 cells with supernatants of unstimulated (open circles) or polyclonally 
stimulated (closed circles) iNKT cells. Left panel, representative plot; right panel, Area under the curve 
(AUC) of n= 5 independent experiments with iNKT lines. (D) Trans-epithelial resistance (TEER) 
measured upon co-culture of Caco-2 cells with supernatants of unstimulated (open circles) or 
polyclonally stimulated iNKT cell lines in the absence (closed circles) or presence of anti IFN/TNF (red 
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circles), anti TNF (blu squares), anti IL17 (purple triangle), anti IFN (green circles) and anti IL13 
(orange triangles) inhibitors. Left panel, representative plot; right panel, Area under the curve (AUC) 
of n= 3 independent experiments. 
 
 
6.3 iNKT cell response to mucosa-associated microbiota 
 
A current hypothesis holds that aberrant activation of pathogenic T lymphocytes in IBD 
patients depends on gut microbiota recognition [153] and it is known that gut microbes are 
potent stimulators of iNKT cell responses [90]. Hence, we asked whether the gut microbiota 
directly activates human intestinal iNKT cells leading to the pro-inflammatory phenotype 
of iNKT cells in IBD patients.  
 
6.3.1 IBD patients experience gut microbial dysbiosis 
We collected the gut mucosa-associated microbiota surgical specimens of IBD patients and 
HD and we evaluated the bacterial composition by 16S rRNA sequencing (Figure 6.10). 
Unweighted UniFrac-based comparisons of the samples isolated from the colon of 9 HD, 7 
UC and 6 colonic CD patients was performed (Figure 6.10A). Principle component analysis 
(PCoA) differentiated healthy microbiota samples from IBD patients, but no differences 
between UC and CD samples were detected (Figure 6.10A). Also, mucosa-associated 
microbiota derived from IBD patients showed a lower α-diversity when compared to HD 
microbiota (Figure 6.10C), confirming previous published data [188]. The taxonomic 
composition of the mucosa-associated microbiome of IBD patients showed an increase of 
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Proteobacteria and Fusobacteria and a decrease in Firmicutes compared to HD. As 
previously reported [189], these alterations were more evident in microbiota samples from 
CD as compared to UC patients (Figure 6.10C). To note, around 15% of the microbial 
ecology at genus level was significantly changed in the samples analyzed. Specific variations 
between colonic IBD and HD-derived samples included the increase of Actinomyces, 
Enterococcus and Streptococcus and the decrease of Roseburia, Blautia, Odoribacter and 
Lachnospinaceae ND3007 (Figure 6.10D). 
These observations confirm that IBD patients are characterized by a state of microbial 
dysbiosis profoundly altering the healthy gut microbiota composition. 
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Figure 6.10 Mucosa-associated microbiota analysis in IBD patients and HD. (A) Microbiome clustering 
based on unweighted Principal Coordinate Analysis (PCoA) UniFrac metrics of mucosa-associated 
microbiota derived from HD (orange triangles), UC (blue dots) and colon CD (red squares) patients. 
(B) Rarefaction curves showing microbial richness based on the Chao1 index. (C) Bar plots of the 
taxonomic composition showing relative abundances >1% of bacterial phyla (D) P value of the 
comparison of the relative abundances of different taxa between colon Crohn’s disease patients 
(upper panel) or Ulcerative colitis patients (lower panels) and healthy donors. Blue bars, taxa enriched 
in healthy donors, red bars, taxa enriched in IBD patients. Statistical significance was assessed with 
Kruskal Wallis test with LSD post-hoc test for more than two groups.  
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6.3.2 iNKT cells acquire a pro-inflammatory phenotype upon exposure to mucus-
associated microbiota 
In order to test whether the pro-inflammatory phenotype of ex-vivo analyzed iNKT cells 
was linked to the distinguished gut microbiota profile of IBD patients, we exposed iNKT 
cells lines in vitro to the mucosa-associated microbiota samples from IBD and HD that we 
had characterized by metagenomic analysis (Figure 6.10). As shown in Figure 6.11, we 
loaded antigen presenting cells (APC) with the microbiota samples that were pre-killed with 
several rounds of heat inactivation. After 2 hours, iNKT cells were added to the well and 
left in co-culture for 36 hours. 
 
Figure 6.11 Antigen presentation assay with human intestinal iNKT cells. Schematic representation of 
the experiment. 
 
All the iNKT cell lines cultured with monocyte-derived dendritic cells in the presence of gut 
microbiota, regardless their origin, were activated and secreted high amounts of pro-
inflammatory cytokines such as TNF, IFNγ and IL-13 (Figure 6.12). Nonetheless, 
qualitatively and quantitatively different responses were observed when iNKT cell lines 
were exposed to the mucosal microbiota isolated from IBD patients compared to that of 
healthy donors (Figure 6.12). These results are in line with the microbial differences we 
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observed in the microbiota of these patients (Figure 6.10) and with the possible presence 
of different TCR-specificities among iNKT cell lines [42]. Interestingly, also HD-derived 
microbiota stimulated iNKT cells and induced the secretion of pro-inflammatory cytokines. 
However, exposure of CD-derived iNKT cell lines to IBD-derived microbiota triggered a 
strong production of pro-inflammatory cytokines, i.e. TNF and IFNγ. Conversely, exposure 
of iNKT cell lines derived from intestinal tissue of HD to the microbiota samples (from IBD 
or HD) did not result in a marked pro-inflammatory cytokine-skewing. In addition, IL-17 
secretion by UC iNKT cell lines was decreased upon exposure to UC-derived microbiota 
(Figure 6.12). 
 
Figure 6.12 iNKT cells react to mucosa-associated microbiota. (B) Cytokine profile of iNKT cell lines (HD, 
UC, CD) co-cultured 36 hours with monocyte-derived dendritic cells exposed to 100 ng of mucosa-
associated microbiota isolated from 8 HD (blue bars), 7 UC (green bars) and 8 CD patients (red bars). 
Quantification of pulled experiments with n=6/8 independent donors per group. Statistical 
significance was calculated with Kruskal Wallis test with Dunn’s post-test for multiple comparison. P 
< 0.05 (*), P < 0.01 (**) were regarded as statistically significant. Outliers were detected with Grubb’s 
test. 
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Next, we tested whether the microbiota-induced pro-inflammatory effect on iNKT cells was 
associated to APC modulation. In vitro differentiated moDC or ex-vivo sorted CD1d+ HLADR+ 
intestinal antigen presenting cells (APC) were exposed to mucosa-associated microbiota 
samples and then their capacity to induce different cytokine profiles in iNKT cells was 
evaluated. Similarly to what observed with moDC, the exposure of CD1d+ sorted intestinal 
APC to gut microbiota, induced a pro-inflammatory activation of iNKT cells with a relevant 
TNF production. Interestingly, only iNKT cells challenged with CD-derived microbiota 
loaded on intestinal APC induced a sustained IL-13 production (Figure 6.13). To note, 
unstimulated intestinal APC were sufficient to induce an IL17 response by iNKT cells (Figure 
6.13).  
In conclusion, iNKT cells become functionally activated upon exposure to human mucosa-
associated microbiota and display a highly skewed pro-inflammatory phenotype. 
 
Figure 6.13  Intestinal antigen presenting cells present bacterial antigens. Frequency of TNF, IFNγ, IL17, 
IL13 positive iNKT cells co-cultured 36 hours with moDC or ex vivo sorted CD1d+MHCII+CD3- intestinal 
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APC in the absence (white bars) or presence of aGalCer (grey bars) or to 100 ng of mucosa-associated 
microbiota isolated from at least 6 HD (blue bars), 4 UC (green bars) and 6 CD patients (red bars) in 
3 independent experiments. Statistical significance was calculated with Kruskal Wallis test with 
Dunn’s post-test for multiple comparison. P < 0.05 (*), P < 0.01 (**) were regarded as statistically 
significant. Outliers were detected with Grubb’s test. 
 
6.3.3 iNKT cells recognize intestinal pathobionts by innate and adaptive 
mechanisms 
Functional activation of iNKT cells is mediated by CD1d-dependent and/or independent 
mechanisms [19].  To explore whether microbiota-induced iNKT cell activation requires 
CD1d presentation, we exposed iNKT cells in vitro to two well-characterized purified 
intestinal pathobionts, known to be present in IBD patients and to mediate inflammatory 
responses [190], [191], i.e. Adherent Invasive Escherichia coli (AIEC) strain LF82 (Figure 
6.14A,C) and Salmonella thyphimurium (B,D). Both strains induced a potent dose-
dependent pro-inflammatory activation of iNKT cells (Figure 6.14A,B). This response 
resulted from a combination of both antigenic and not-antigenic (innate) stimulation, as 
demonstrated by its only partial inhibition after CD1d blockade (Figure 6.14C,D).  
Noteworthy, in our cohort of patients the genus Salmonella was detected almost 
exclusively in mucus-associated IBD samples (Figure 6.14E), while the Escherichia/Shighella 
genus was detected also at lower levels in HD samples (Figure 6.14F). 
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Figure 6.14 Human iNKT cells respond to stimulation with pathogenic intestinal bacterial strains. (A, B) 
IFNγ (left panels), TNF (middle panels) and IL-13 (right panels) in the supernatants of iNKT cells co-
cultured 36 hours with monocyte-derived dendritic cells exposed to increases doses of the Adherent-
invasive E. coli LF82 (AIEC, A) and of Salmonella thyphimurium (B). White dots, stimulation in the 
presence of anti-CD1d blocking antibody. (C,D) Cumulative representation of IFNγ production upon 
exposure to AIEC (B) or Salmonella thyphimurium (D) in at least 3 independent experiments with 2 
different HD clones, 3 different CD and 3 different UC clones (E,F). Escherichia/Shigella (E) and 
Salmonella (F) genus in colonic HD (n=9), UC (n=7), colonic CD (n=6), ileal HD (n=7), and ileal CD (n=7). 
Statistical significance was calculated with Kruskal Wallis test with Dunn’s post-test for multiple 
comparison. P < 0.05 (*), P < 0.01 (**) were regarded as statistically significant. Outliers were 
detected with Grubb’s test. 
 
6.3.4 iNKT cells become pathogenic against intestinal epithelial cells upon 
microbiota stimulation 
Further, to test if the pro-inflammatory iNKT cell activation driven by mucosa-associated 
microbiota might induce specific pathogenic functions against the intestinal epithelium, 
iNKT cells were exposed to the mucosa-associated IBD-derived microbiota. After 24 hours 
of activation iNKT cells were magnetically sorted and left in culture for 4 hours. Their 
supernatant was then collected and put on Caco2 epithelial monolayers in transwells 
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(Figure 6.15A). Consistent to our previous findings, microbiota-activated iNKT cells 
secreted pro-inflammatory cytokines such as TNF and IFNγ (Figure 6.15B).   
Microbiota- activated iNKT cells, regardless of their origin, manifested pathogenic activities 
affecting epithelial cell monolayer integrity, as demonstrated by decrease of Trans 
Epithelial Resistance (TEER) (Figure 6.15C). Additionally, specific inhibition of iNKT-cell 
derived TNF and IFNγ abolished their pathogenic functions towards epithelial cell integrity 
(Figure 6.15D).  
These findings suggest that exposure to mucosa-associated bacteria is sufficient to drive 
both innate and adaptive iNKT cell pro-inflammatory activation. Once activated, intestinal 
iNKT cells secrete pro-inflammatory cytokines conferring pathogenic features towards the 
intestinal epithelium. 
 
Figure 6.15 Microbiota-stimulated human iNKT cells are pathogenic against epithelial cells. (A) 
Schematic representation of the experiment. (B) Multiplex analysis of TNF, IFN, IL-17A and IL-13 
concentrations in the supernatants of iNKT cells co-cultured with moDC alone (open circles) or with 
moDC stimulated with intestinal microbiota (closed circles) (C) Trans-epithelial resistance (TEER) 
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measured upon co-culture of Caco-2 cells with supernatants of iNKT cells co-cultured with moDC 
alone (open circles) or with moDC stimulated with intestinal microbiota (closed circles). Left panel, 
representative plot; right panel, Area under the curve (AUC) of n=4 independent experiments with 
iNKT cell lines. (D) Trans-epithelial resistance (TEER) measured upon co-culture of Caco-2 cells with 
supernatants of iNKT cells with moDC alone (open circles) or with moDC stimulated with intestinal 
microbiota (closed circles) in the absence (closed circles) or presence of anti IFN/TNF (grey circles) 
inhibitors. Left panel, representative plot; right panel, Area under the curve (AUC) of n=3 independent 
experiments.  Statistical significance was calculated with Mann-Whitney test for comparison between 
two groups and Kruskal wallis test with Dunn’s post-test for multiple comparison. P < 0.05 (*), P < 
0.01 (**), P < 0.001 (***) were regarded as statistically significant. Outliers were detected with 
Grubb’s test. 
 
6.3.5 Gut microbiota is responsible for iNKT cell pro-inflammatory activation in 
vivo during intestinal inflammation 
Finally, we aimed at recapitulating in vivo the effects of bacteria exposure on pro-
inflammatory activation of iNKT cells during intestinal inflammation. To this goal, we 
depleted gut microbiota in mice by the use of a broad-spectrum antibiotics cocktail 
(Ampicillin, Neomycin, Metronidazole, Vancomycin) during DSS-induced colitis (Figure 
6.16A). For this setting, we adopted the DSS-induced chronic colitis model in which DSS 
was administered in three serial cycles of DSS and water alternation. This model better 
resembles the IBD patient intestinal inflammation due to its chronic timeframe and its 
massive epithelial disruption and bacterial translocation [155].  
Chronic administration of DSS resulted in dramatic weight loss (Figure 6.16B), epithelial 
barrier ulceration and hyperplasia (Figure 6.16C) and upregulation of a panel of pro-
inflammatory genes (Figure 6.16D). All these signs of inflammation were strongly reduced 
upon microbiota depletion (Figure 6.16B-D), consistently to reported data [192].  
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Figure 6.16 Antibiotics driven gut microbiota depletion reduces intestinal inflammation in a chronic 
model. (A) Representative scheme of the treatment. cDSS, chronic DSS. ABX, mix of ampicillin, 
neomycin, vancomycin and metronidazole. (B) Weight curve, (C) H&E staining (scalebar 100µm) and 
cumulative colonic histological score and (D) colonic expression of pro-inflammatory genes in mice 
untreated (white bars), DSS-treated (dark grey bars) and DSS+ ABX-treated (light grey bars). 
Statistical significance was calculated with Kruskal Wallis test with Dunn’s post-test for multiple 
comparison. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) were regarded as statistically significant. 
Outliers were detected with Grubb’s test. 
 
After having performed a fluorescent in situ hybridization of the colonic tissues, we 
observed that DSS induced a marked bacterial translocation into the intestinal lamina 
propria, while antibiotics treatment abrogated this effect (Figure 6.17).  
This result confirmed that in this experimental setting the colocalization, and thus the 
direct interaction, between gut microbiota and the mucosal immune system is abrogated. 
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Figure 6.17 Antibiotic treatment reduces bacteria translocating into the lamina propria during intestinal 
inflammation. Fluorescent in situ hybridization of bacterial DNA detected with with Eubacteria probes 
(Eub-488, green) on paraffin embedded colonic tissues obtained from untreated, DSS- and DSS+ ABX-
treated mice. 
 
DSS + Abx treated mice showed also a strong decrease in colonic expression levels of 
CXCL16, the chemokine responsible for iNKT cell chemoattraction into the gut, and of its 
receptor CXCR6 were strongly diminished (Figure 6.18A). 
To assess whether the lack of bacteria in the lamina propria could impact on the mucosal T 
cell compartment activation status, we analyzed the lamina propria infiltrate by 
flowcytometry. As expected, colonic iNKT and CD4+ T cell frequencies (Figure 6.18B-C) and 
absolute numbers (Figure 6.18B-C) were decreased in mice treated with DSS in the 
presence of antibiotics. 
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Figure 6.18  Antibiotic treatment reduces CD4+ T and iNKT cell accumulation into the lamina propria 
during intestinal inflammation. (A) Colonic expression levels of cxcl16 and cxcr6 in mice untreated 
(white bars), treated with DSS (black bars) or with DSS + ABX (dark grey bars). (B) Representative dot 
plots (C) frequency and absolute numbers of colonic iNKT cells and CD4+ T cells in mice untreated 
(white bars), treated with DSS (black bars) or with DSS + ABX (dark grey bars). Statistical significance 
was calculated with Kruskal Wallis test with Dunn’s post-test for multiple comparison. P < 0.05 (*), P 
< 0.01 (**), P < 0.001 (***) were regarded as statistically significant. Outliers were detected with 
Grubb’s test. 
 
Most importantly, the reduction of intestinal bacterial translocation into the lamina propria 
during intestinal inflammation significantly inhibited proliferation and activation, 
determined through Ki67 and CD69 staining, respectively (Figure 6.19A), of both iNKT and 
CD4+ T cells. 
Interestingly, also the cytokine profile of iNKT cells, but not the one of CD4+ T cells, was 
affected. The secretion of the pro-inflammatory TNF, IFNγ and IL-17 cytokines were 
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enhanced upon DSS administration and greatly impaired in the absence of translocating 
bacteria in the lamina propria (Figure 6.19B). 
 
 
Figure 6.19. Intestinal microbiota elimination reduces pro-inflammatory activation of iNKT cells during 
experimental chronic colitis.  (A) Absolute numbers of Ki67+ and CD69+ colonic iNKT cells (left panel) 
and CD4+ T cells (right panels) and (B) frequency of TNF, IFNγ and IL-17 producing iNKT cells (left 
panels) and CD4+ T cells (right panels) in mice untreated (white bars), treated with DSS (Black bars) 
or with DSS + ABX (dark grey bars). Statistical significance was calculated with Kruskal Wallis test with 
Dunn’s post-test for multiple comparison. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) were regarded 
as statistically significant. Outliers were detected with Grubb’s test. 
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Collectively, these data indicate that exposure to the intestinal microbiota is required for 
iNKT cell pro-inflammatory activation in the colonic mucosa, and that iNKT and CD4+ T cells 
manifest in vivo similar functional properties during intestinal inflammation. 
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7 Discussion II 
 
A functional involvement of iNKT cells has been suggested for a wide variety of human 
autoimmune disorders including multiple sclerosis [193], rheumatic diseases [194] and 
asthma [195]. Conversely, iNKT cell contribution to IBD pathogenesis is still incompletely 
understood. By studying human intestinal tissues, we demonstrated that iNKT cells 
infiltrate the intestinal mucosa of IBD patients (Section 6.1) and that they display a pro-
inflammatory phenotype and pathogenic features upon exposure to intestinal mucosa-
associated microbiota (Section 6.3). Thus, to our knowledge, this is the first comprehensive 
report of human intestinal iNKT cells in IBD patients. 
Technical difficulties hampered for long time univocal attribution of iNKT cell pathogenic 
or protective roles in human diseases. Before the advent of the Tetramer technology, iNKT 
cells could be identified either by the co-expression of NK-related markers (CD56 and/or 
CD161, the human counterpart of the murine NK1.1) with CD3, by the reaction to CD1d 
stimulation, or by Vα24 TCR expression. It is believed therefore that old studies on iNKT cell 
functions most likely included different subsets, such as CD1d-restricted Type2 NKT, MAIT 
and γδ T cells [196].   
In addition, the frequency of circulating and tissue-resident iNKT cells is greatly variable 
among individuals [19]. The analysis of the LPMC isolated from IBD patients and non-IBD 
donors confirmed this relevant intra-individual variability also for intestinal iNKT cell 
frequencies (Figure 6.1), that did not correlate to any epidemiologic or clinical parameter.  
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Functionally different subsets of iNKT cells can be distinguished according to the expression 
of CD4 [197], whose engagement by CD1d molecules potentiates iNKT cell activation [19]. 
Human and murine tissue-derived iNKT cells are mostly CD4+ [51], and we here observed 
that up to 80% of human intestinal iNKT cells express CD4 both in HD and IBD patients 
(Figure 6.2).  CD161 expression, instead, has been specifically associated to intestinal tissue 
distribution of several T cell subsets, including MAIT cells and TCR γδ cells [198]. In our 
study, intestinal iNKT cells from IBD patients and HD mainly co-expressed CD4 and CD161 
and secreted substantial amounts of pro-inflammatory cytokines (Figure 6.2 and Figure 
6.4). These data are in accordance with previous reports indicating that CD4+ CD161+ 
intestinal T cell subsets might exert specific pathogenic functions, both in CD [109] and UC 
[115] patients. Those reports, though, either excluded iNKT cells from the analysis [109] or 
focused on type II sulfatide-specific NKT subsets [24], [115].  
Here we also reported that, both in mice and men, pro-inflammatory cytokine secretion is 
a key functional attribute of intestinal iNKT cells. Distinct Th subsets in the gut are known 
to secrete specific Th1 or Th2 cytokines, although context-dependent functional plasticity 
has been demonstrated for murine and human intestinal Th subsets [35], [181]. Similarly 
to murine [51] and PB-derived cells [199], in our analyses intestinal iNKT cells possess an 
intrinsic capability to secrete a broad array of Th1, Th2 and Th17 cytokines. This 
characteristic, shared with other innate populations, could be an evolutionary conserved 
functional requirement for cells endowed with patrolling of mucosal surfaces [96].   
Healthy and IBD-derived mucosa-associated microbiota were capable to efficiently activate 
in vitro human intestinal iNKT cells, stimulate cytokine secretion and induce pathogenic 
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functions (Figure 6.12). Several evidences suggest a reciprocal influence of iNKT cells and 
the intestinal gut microbiota [71], [89], [94]. iNKT cells affect murine gut colonization by 
commensal microorganisms [94] while during early neonatal and postnatal stages of 
development, commensals bacteria negatively shape iNKT cell repertoire [71]. The 
commensal B. fragilis, known to produce lipid antigens controlling homeostatic iNKT cell 
proliferation and activation [21] was detected only in two healthy donors and three colon 
CD-derived samples. Further studies are required to understand if a reduction of B. fragilis 
in IBD patients might correlate with pro-inflammatory functional skewing of human 
intestinal iNKT cells.  
As previously discussed, IBD patients harbor significant variations in the intestinal 
microbiota composition as compared to non-IBD controls [118]–[122], defined by an 
overall decrease of α-diversity but also by alterations of microbial taxa relative abundances, 
i.e. specific increase in Proteobacteria (such as adherent invasive E. coli and 
Enterobacteriaceae in CD) and decrease in Firmicutes  (such as F. prausnitzii) [125]. These 
variations were confirmed in our samples (Figure 6.10), including the decrease in the 
butyrate-producing Roseburia, Blautia [118] and Odoribacter [119] in IBD versus HD 
donors, as well as the increase of Erysipelotrichaceae in UC patients [121]. 
From a mechanistic point of view, our data suggest that the loss of the barrier integrity 
might be the critical event exposing iNKT cells to the mucosa-associated microbial ecology 
and to luminal metabolites. Once in contact with the microbiota, as we showed (Figure 
6.17), intestinal iNKT cells could be activated through both TCR-dependent and 
independent mechanisms. 
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So far, few bacteria-derived glycosphingolipid antigens capable to specifically activate iNKT 
cells have been identified, including those isolated from the cell wall of Gram-negative 
Sphingomonas spp [200], Borrelia burgdorferi [201] and Mycobacteria [202]. Conversely, 
no iNKT-specific lipid antigens have been isolated from adherent invasive E. coli and 
Salmonella, two well-known intestinal pathobionts consistently present in our IBD and non-
IBD-derived samples and which efficiently stimulated iNKT cell responses partially through 
CD1d-dependent mechanisms (Figure 6.14). Abundant evidences instead exist that iNKT 
cells can be activated in an innate fashion by microbial products such as LPS [203], either 
directly through TLR4 binding [204] or after IL-12/IL-18-mediated activation of LPS-
stimulated dendritic cells [45]. We speculate that in addition to an innate microbiota-
dependent iNKT cell activation, endogenous lipid antigens might be induced or upregulated 
in bacteria-stimulated moDC, thus explaining the observed antigen-specific activation by 
iNKT cells. 
Upon exposure to the commensal intestinal microbiota, activated intestinal iNKT cells 
secreted a broad array of cytokines, including TNF and IFNγ, which are known to increase 
intestinal permeability [96], and that were directly responsible for in vitro iNKT cell 
pathogenic functions. We have recently demonstrated that human Th17 cells isolated from 
the ileum of CD patients co-secrete pro-inflammatory IFNγ and TNF conferring pathogenic 
properties against the intestinal epithelium (Appendix III and [35]), suggesting that during 
intestinal inflammation iNKT cells and conventional CD4+ T cells might manifest a similar 
behavior. 
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Differently to conventional Th cells, though, iNKT cells can also behave as innate cells that 
rapidly and massively respond to the commensal microbiota-driven activation. 
Abolishment of bacterial translocation by broad-spectrum antibiotic treatment during 
experimental chronic colitis efficiently blocked iNKT (and conventional CD4+ T cells) 
activation and cytokine secretion, recapitulating in vivo what observed in vitro and 
providing a rationale for possible targeted interventions aimed at containing immune cell 
responses in IBD patients.  
In conclusion, our study sheds novel light on the pathogenic functions of iNKT cells during 
intestinal inflammation in IBD patients. Moreover, it suggests that a wider knowledge of 
the human microbiome at the community-level, rather than on single microbial species, 
can better contribute to the final understanding of the mechanisms of immune modulation. 
Finally, targeting the mucosa-associated microbiota recognition by iNKT cells might be a 
promising approach to control their pro-inflammatory activity and intestinal inflammation. 
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8 Conclusions 
 
With this thesis we provided solid evidence that a strict interaction between the gut 
microbiota and intestinal conventional and non-conventional T cells is in place. We 
observed that inflammation-induced and antibiotic-driven dysbiosis affect T and iNKT cell 
phenotype and functions (Sections 4.1 and 4.2). Moreover, a drastic manipulation of the 
microbiota community through Faecal Microbiota Transplantation (FMT) results in a 
modulation of the whole mucosal immune response, encompassing both epithelial cell 
functions, and innate and adaptive branches of mucosal immunity (Sections 4.3-4.6). 
Further, we performed a comprehensive analysis on the phenotypic and functional shaping 
of human iNKT cells mediated by IBD-associated dysbiotic bacterial communities (Chapter 
6).  
In the past years, pivotal studies revealed the existence of mutual mechanisms of 
regulation between the intestinal microbiota and iNKT cells [21], [71], [89], [94]. These 
observations were mainly obtained by taking advantage of murine experimental models 
completely devoid of commensal microbiota communities, i.e. the Germ free (GF) mice. GF 
mice proved to be essential in demonstrating causative associations between single-strain 
bacteria and specific T cell subsets [58], [75], [76], [205] and to gain functional insights into 
host-microbe interactions in health and disease [62], [127]. Nonetheless, it must be kept in 
mind that the absence of the microbiota in the early phases of life importantly impacts on 
the development of a mature host immune system, thus shaping immune functions in the 
adults [71], [88]. This caveat needs to be taken in consideration when using GF mice to 
study microbiota-related immune responses. In the study presented in this thesis, we faced 
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the need to bypass this vicious circle and to find suitable experimental models to assess the 
effects of gut microbiota manipulation on immune cells that had undergone a normal 
development and a correct shaping from bacterial components. For these reasons, we 
decided to adopt antibiotics treatment on mice reared in specific pathogen free (SPF) 
conditions, being aware that this model, as well, bears some pitfalls. The antibiotics used 
in our experiments had a wide spectrum of action, but their specificity could not cover the 
whole microbial population, and antibiotic administration does not affect other non-
microbial components of the microbiota, such as viruses and fungi. In addition, in 
experimental FMT, antibiotics per se could negatively influence the engraftment niches of 
bacteria. Nonetheless, keeping these caveats in mind, we adopted this type of 
experimental setting to study at least some aspects of microbiota-driven immune response 
in adults. 
In this work we observed the presence of a negative regulation on the intestinal iNKT cell 
repertoire exerted by the gut microbiota under homeostatic conditions (Figure 4.6), 
confirming what previously shown in GF mice [21], [71]. Several mechanisms have been 
shown to explain this regulation, i.e. modulation of CXCL16 production by intestinal 
epithelial cells (IEC) [71], bacterial antigen presentation inhibiting iNKT cell proliferation 
[21] and expansion of cytotoxic CD8+ T cells [92]. 
Moreover, we also described a marked expansion of the intestinal iNKT cell population in 
another context of dysbiosis, i.e. DSS-driven inflammation. The murine model of DSS 
induced colitis is characterized by epithelial toxicity, disruption of the intestinal physical 
barriers and massive translocation of luminal dysbiotic bacteria and metabolites in the 
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lamina propria. These events, in turn, trigger the recruitment and expansion of both innate 
and adaptive immune cells. Thus, it is not surprising, though nobody explicitly addressed it 
before, that also iNKT cells accumulate in the lamina propria during this chemically induced 
inflammation. Many indirect evidences suggested an iNKT cell involvement during DSS-
induced inflammation, i.e. αGalCer administration was shown to ameliorate experimental 
colitis in a CD1d dependent manner [206], and Jα18-/- mice were shown to experience a 
worsening of colitic symptoms that were ameliorated by WT iNKT cell adoptive transfer 
[207]. In contrast, in another murine model of intestinal inflammation, i.e. the oxazolone 
induced colitis model, iNKT cells were indicated as the main drivers of inflammation due to 
a marked Th2 (or NKT2) activity [114], [208]. Here, we observed that during DSS-induced 
colitis, iNKT cells massively secreted Th1/17 (or NKT1/17) types of cytokines such as IL-17, 
IFNγ and TNF (Figure 4.3 and Figure 6.19). These data perfectly recapitulated what 
observed in the lamina propria of IBD patients (Figure 6.4) and upon in vitro stimulation of 
human iNKT cells with IBD-associated microbiota (Figure 6.12). 
DSS-induced intestinal inflammation strictly requires the presence of gut microbiota, since 
both DSS-treated GF mice [192] and antibiotics treated mice (Appendix II and [91]) have 
been shown to display reduced signs of inflammation. Consistently, when we blocked 
luminal bacterial translocation administering a broad-spectrum antibiotic mix in 
combination to chronic (Figure 6.17) or acute (Appendix II and [91]) DSS treatment, we also 
observed an overall reduction in both macroscopic tissue inflammation (histopathology 
and pro-inflammatory gene expression, Figure 6.16) and T and iNKT cell accumulation in 
the intestinal lamina propria (Figure 6.18). Importantly, also iNKT cell pro-inflammatory 
activity was significantly decreased (Figure 6.19). Altogether these findings indicate that 
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the pathological breach of epithelial barrier and the following entrance of luminal bacteria 
are additional triggers of intestinal iNKT cell expansion and activation. These results also 
suggest that microbiota depletion during pathologic conditions might not lead to iNKT cell 
pool expansion as it happens during intestinal homeostasis. One possible explanation for 
these findings is that the cell types involved in microbiota-associated iNKT cell regulation 
(i.e. epithelial cells, antigen presenting cells and/or other T cell subsets) lose their full 
homeostatic activity and fail in regulating iNKT cell repertoire during pathologic conditions. 
Conversely, when antibiotic-treated mucus-associated and luminal bacteria were 
transplanted in mice after DSS administration, intestinal iNKT cell population boomed, 
becoming significantly more abundant than upon DSS administration alone (Figure 4.28). 
We believe that the key to provide a possible explanation for these apparently conflicting 
results is to take into consideration the chronological timing of the events in the different 
experimental settings. DSS-induced inflammation, antibiotic administration and 
reconstitution of the gut microbiota by FMT generate distinct and independent microbiota-
associated functional events that, if occurring with a precise timing, can work in synergism 
and lead to intestinal iNKT cell expansion and/or recruitment. 
In the attempt to reconcile the observations obtained in the different experimental 
conditions, we here propose a model (Figure 8.1) describing the events (“triggers”) 
occurring in the intestinal mucosa and involving epithelial cells, gut microbiota and iNKT 
cells in homeostatic and inflammatory conditions.  
During DSS-induced inflammation, the highly destabilizing conditions of epithelial breach 
and the following microbiota entry induce iNKT cell expansion in a very short time (trigger 
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1). Upon antibiotic treatment, instead, reduction of the luminal bacterial load and α-
diversity occurs, likely triggering the already described microbiota-associated release of the 
negative regulation of iNKT cell pool (trigger 2) [21], [71]. After recolonization with a normal 
microbiota achieved through FMT, normal iNKT cell levels are restored. Consistently, when 
colitis is induced during broad spectrum antibiotic treatment, even if the DSS has caused 
epithelial breach, the absence of bacteria impedes the induction of the events associated 
to trigger 1. Conversely, when the DSS-induced microbial translocation into the lamina 
propria is sequentially followed by the transplant of an antibiotic-treated donor microbiota 
with low α-diversity and bacterial load, trigger 1 and trigger 2 add together and induce a 
boom in iNKT cell pool. 
Figure 8.1 Schematic representation of intestinal iNKT cell regulation by gut microbiota in health and 
disease 
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In order to prove the validity of this model further experiments are needed. It would be 
interesting to understand whether the regulation of intestinal iNKT cells would be affected 
by a switch in the timing between trigger 1 and trigger 2 occurrence. Indeed, we plan to 
treat mice with antibiotics mix or with the transplant of antibiotic-treated mucus-
associated and luminal bacteria, prior to the induction of colitis with DSS. In this way we 
believe we will be able firstly to trigger iNKT cell expansion, thanks to the release of 
microbiota dependent-iNKT cell inhibition, and then induce epithelial disruption and 
translocation of the remaining bacteria into the lamina propria. We will likely have to wait 
for a period of rest between the two treatments to allow a bacterial recolonization 
sufficient to trigger colitis without restoring a complete inhibition on iNKT cells.  
This experiment will give us additional information on microbiota-iNKT crosstalk, hinting 
also at the possibility to translate this knowledge into clinics. Knowing that iNKT cells have 
been shown to drive IBD pathogenesis in patients and in murine models [24], [209] and 
that they can importantly contribute to intestinal inflammation through epithelial toxicity 
(Chapter 6), it would be relevant to shed light on their mechanisms of regulation during 
both intestinal homeostasis and disease. 
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